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The present work describes the preparation of three novel series of compounds based on the structure of
goniothalamin, a natural styryl lactone which has been found to display cytotoxic and antiproliferative
activities against a variety of cancer cell lines. A focused library of 29 novel goniothalamin analogues
was prepared and evaluated against seven human cancer cell lines. While the c-pyrones and the aza-
goniothalamin analogues were less potent than the lead compound, 2,4-dimethoxy analogue 88 has
shown to be more potent in vitro than goniothalamin against all cancer cell lines evaluated. Furthermore,
it was more potent than doxorubicin against NCI-ADR/RES, OVCAR-03 and HT-29 while being less toxic to
human keratinocytes (HaCat). The 3,5-dimethoxy analogue 90 and 2,4,5-trimethoxy analogue 92 also dis-
played promising antiproliferative activity when compared to goniothalamin (1). These results provide
new elements for the design and synthesis of novel representatives of this family of natural compounds.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Cancer treatment includes many strategies and chemotherapy
plays a central role in curing the disease or considerably prolong-
ing and improving the patient’s quality of life. However, resistance
of tumor cells to multiple structurally unrelated cytotoxic drugs
(multidrug resistance) is nowadays the major limitation to the suc-
cessful chemotherapeutic treatment of disseminated neoplasms. In
this regard, natural products remain a privileged source for the dis-
covery and the development of new compounds for cancer
treatment.1
During an ongoing program to identify new candidates for can-
cer treatment, goniothalamin (1) (Fig. 1) was recognized as a good
lead compound with signiﬁcant cytotoxic and antiproliferative
activities against a variety of cancer cell lines, including kidney,
prostate, breast carcinoma, leukemia, lung and liver.2,3 Originally
isolated from various species of the genus Goniothalamus,4 this sty-
ryl lactone also presents other important biological activities
including antimicrobial,5 antifungal,6 larvicidal,7 insecticidal8 and
trypanocidal.9
Several efforts have been made in an attempt to elucidate the
mechanism responsible for the cytotoxic and antiproliferativex: +55 19 3521 4892.
evier OA license.properties displayed by goniothalamin and analogues. Some stud-
ies indicate the apoptotic activity of goniothalamin in cancer cell
lines through different pathways, including the increase in the
expression of caspases 3, 7 and 9,10 increase in the expression of
pro-apoptotic protein Bax,11 inhibition of constitutive NOS12 and
inhibition of nucleus-cytoplasm transport mediated by CRM1.13
Recently, in vivo studies performed by our group with goniothal-
amin in a solid tumor experimental model in mice conﬁrmed its
low acute toxicity and suggested a relationship between anticancer
and anti-inﬂammatory activities, with the anti-inﬂammatory
activity favoring the antiproliferative activity itself.14
In order to ﬁne tune the cytotoxic activity and to better under-
stand its mode of action, the synthesis of new goniothalamin deriv-
atives continues to attract interest. Such analogues could be useful
for the elucidation of structure–activity relationships (SARs) and
could result in the development of compounds with higher activity
and selectivity.
A limited number of structure–activity relationship studies of
goniothalamin and synthetic analogues established some of the
relevant structural requirements for the cytotoxic activity
(Fig. 2).15
Mu and co-workers described the semi-synthesis of 19 deriva-
tives of the natural isomer (R)-goniothalamin (only most active
compounds were shown) and found that 2- and 4-nitro analogues
2 and 3, respectively, were the most active against promyelocytic
leukemia (HL-60) and human lung carcinoma (A549) cells. On
OO
Figure 1. Chemical structure of (R)-goniothalamin (1).
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in expressed poor antitumor activities.16
Later, Pilli and co-workers prepared both enantiomers of gonio-
thalamin and it was found that (S)-goniothalamin (15) was 1,600-
fold more potent than (R)-goniothalamin (1) against kidney cancer
cells (786-0), possessing IC50 in the nanomolar range. Synthesis of
analogues 16–23 also allowed the identiﬁcation of the pharmaco-
phoric groups responsible for the high antiproliferative activity
and selectivity displayed by (S)-goniothalamin against the cancer
cell line 786-0. Analogues 21–23 lacking one or two double bonds
were marginally active or inactive, showing that the endo and exo
double bond related to the pyrone ring are essential for the activity
against kidney cancer (786-0) cell line.2 From this study and others
performed with fostriecin and cytostatin,17 the a,b-unsaturated d-
lactone moiety seems to be a key feature for activity as a result of
its ability to act as a Michael acceptor in the presence of biomole-
cules containing nucleophilic amino acid (e.g. cysteine, lysine, ser-
ine and threonine) or guanine residues.
In the same study, goniothalamin analogue 14 displaying Z-con-
ﬁgured double bond in the styryl moiety, was 2-fold less active
against most of the cell lines evaluated. Having this in mind, Çag˘ır
and co-workers prepared and evaluated a series of 2-naphtyl and
3-quinolyl derivatives in order to better understand the role of
the exo double bond in the antiproliferative activity.18 It was ob-
served that analogues 24 and 25 had slightly better antiprolifera-
tive activities against prostate (PC-3) and breast (MCF-7) cancer
cell lines compared to goniothalamin (1), which may be relatedR2
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Figure 2. Analogues of goniothalamto higher conformational restriction or steric hindrance due to
the 2-naphtyl and 3-quinolyl substituents. Interestingly, 1-naph-
thyl substitution in the lactone ring dramatically enhanced the
cytotoxic activity, especially when it posses a methyl group in
the 2 or 3 position. For example, analogue 31 was 80- and 40-fold
more potent against PC-3 and MCF-7 cells, respectively, in compar-
ison with goniothalamin (1).
Gademann and co-workers designed a series of goniothalamin
analogues aiming to evaluate the impact of the distance of the phe-
nyl group to the lactone in the biological activity.13 In the event,
truncated goniothalamin analogues 32, 34 and 35 were prepared.
Additionally, extended analogues containing a phenyl 36 or a triple
bond 33 spacer were obtained. These compounds were investi-
gated in the inhibition of CRM1-dependente nuclear export of
the protein kinase Rio2 in HeLa cells, which could be associated
to potent antiproliferative effects. Of all the analogues tested, only
32 showed activity similar to goniothalamin and analogues 33–36
did not display signiﬁcant inhibition of nuclear export.
Recently, Pilli et al. evaluated racemic goniothalaminagainst sev-
eral human cancer cell lines and it was observed that the racemate
exhibited similar antiproliferative activity proﬁle compared to both
enantiomers against glioma (U251), breast expressing themultidrug
resistance phenotype (NCI-ADR/RES), kidney (786-0), lung (NCI-
H460) and prostate (PC-3) cancer cells. However, in analogy to (R)-
goniothalamin (1), the racemic form displayed higher potency
against melanoma (UACC-62), breast (MCF-7), ovarian (OVCAR-03)
and colon (HT-29) cancer cells than (S)-goniothalamin.14
In our previus work, 4-methoxy substitution afforded the highly
active and selective derivative 18 against breast cancer cells
expressing the multidrug resistance phenotype (NCI-ADR/RES),
with IC50 in the nanomolar range. In addition, a recent work per-
formed to evaluate the bioactivity of stilbenes demonstrated that
those having methoxy groups exhibited stronger inhibition of tu-
mor growth in roundworms when compared to the hydroxylated
ones.19 Methoxylation can increase bioactivity in vivo since stilb-O
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in (1) reported in the literature.
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Scheme 1. Synthesis of compounds 40–46. Reagents and conditions: (a) BF3OEt2, Et2O, 78 C, 3 h; (b) TFA (1.3 equiv), CH2Cl2, 0 C to rt, 40 min (59–70%, over 2 steps); (c)
Styrene (3–5 equiv), Grubbs’ second generation catalyst (2 mol %), CuI (3 mol %), CH2Cl2, reﬂux, 3–6 h (56–79%).
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Scheme 2. Synthesis of compounds 47–49. Reagents and conditions: (a) DDQ
(1.7 equiv), benzene, reﬂux, 3 h (78–85% yield).
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slower than those with hydroxyl groups. Therefore, the synthesis
of poly-methoxylated goniothalamin analogues stands as a prom-
ising approach to improve the potency and selectivity of this family
of compounds as well as the incorporation of ﬂuorine into the
structure of the lead compound which has become a common tool
in medicinal chemistry for improving the pharmacological proﬁle
of bioactive compounds.20
Additionally, the synthesis of aza-analogues is another strategy
employed to prepare compounds with better bioavailability. Sev-
eral reports in the literature have validated this approach,21 the
most representative case being ixabepilone, an epothilone B ana-
logue with increased stability due to isosteric replacement of the
lactone ring by a lactam one,22 which has been approved by U.S.
Food and Drug Administration (FDA) for the treatment of patients
with metastatic or locally advanced breast cancer resistant to
treatment with an anthracycline and a taxane.23 The synthesis of
aza-analogues of goniothalamin would also enable further evalua-
tion of the importance of the Michael acceptor site for the cytotoxic
and antiproliferative activities of this family of compounds since
a,b-unsaturated d-lactams are less electron deﬁcient than a,b-
unsaturated d-lactones thus impacting their biological proﬁle.
Along this line of reasoning, the synthesis of dihydro-c-pyrones
analogues of goniothalamin seemed to be of interest as vinylogous
lactones are expected to display electron acceptor properties in the
range of a,b-unsaturated d-lactones and a,b-unsaturated d-lactams
as changing the oxygen atom from alpha (lactones) to gamma po-
sition (c-pyrones) is expected to change the electron deﬁciency of
the a,b-unsaturated system. c-Pyrones are considered to be an
important class of natural products isolated mainly from marine
organisms and displaying structural diversity.24 Most biological
studies with c-pyrones were performed in marine ecosystem and
less attention has been devoted to their potential as prototypes
for the development of new drug candidates. Furthermore, despite
the considerable number of synthetic methodologies, to our
knowledge no evaluation of the cytotoxic activity of simple dihy-
dro-c-pyrones against cancer cell lines have been reported.
Herein, we report the design and synthesis of a focused library
of goniothalamin analogues displaying the d-lactone, d-lactam andc-pyrone structural motifs and their in vitro evaluation against se-
ven human cancer cell lines: U251 (glioma), MCF-7 (breast), NCI-
ADR/RES (breast expressing the multidrug resistance phenotype),
786-0 (kidney), NCI-H460 (lung non-small cells), OVCAR-03 (ovar-
ian) and HT-29 (colon).
2. Results and discussion
2.1. Chemistry
The synthetic strategy aiming the preparation of dihydro-c-pyr-
ones is outlined in Scheme 1. Oleﬁn 40 was prepared using opti-
mized conditions of the reported procedure.25 The boron
triﬂuoride catalyzed hetero Diels–Alder reaction (HDA) of Dani-
shefsky´s diene 37 with acrolein 38 afforded a mixture of 39/40
(1:2 molar ratio), due to the competitive Mukaiyama aldol reac-
tion. Adduct 39 was cyclized after treatment with triﬂuoroacetic
acid, allowing to obtain dihydro-c-pyrone 40 in 59–70% yield, over
two steps. Next, an oleﬁn cross metathesis reaction with various
styrenes in the presence of Grubbs’ second generation catalyst
(2 mol %) and CuI (3 mol %) as additive, in reﬂuxing CH2Cl2, affor-
ded the desired dihydro-c-pyrones 41–46 in moderate to good
yields (56–79%). The exclusive formation of the E isomer (>95:05
by 1H NMR) was conﬁrmed by NMR analysis of the coupling con-
stants of the double bond (J = 16.0 Hz).
The synthesis of c-pyrones 47–49 was performed using oxida-
tion of the corresponding dihydro-c-pyrones 41, 43 and 44 with
DDQ in reﬂuxing benzene as shown in Scheme 2 (78–85% yield).
In order to evaluate the importance of the styryl moiety of the
dihydro-c-pyrones to the antiproliferative activity, aryl derivative
50was prepared according to the methodology described by Rawal
and Huang.26 Next, the synthesis of the c-pyrone 51 was per-
formed using the previously reported DDQ oxidation (Scheme 3),
albeit in longer reaction time (15 h), in 87% yield. Finally, the a-
bromo and a-iodo-dihydro-c-pyrones 52 and 53, respectively,
were prepared according to the protocol developed by Evans
et al.27 Thus, treatment of compound 50 with iodosobenzene diac-
etate and trimethylsilyl bromide, in the presence of pyridine, fur-
nished the a-bromo-dihydro-c-pyrone 52 in 81% yield, as shown
in Scheme 3. Iodination of the dihydro-c-pyrone 50was performed
using molecular iodine under essentially identical reaction condi-
tions, giving a-iodo-dihydro-c-pyrone 53 in excellent yield (92%).
The synthesis of the racemic form of the triﬂuoromethylated
and methoxylated analogues of goniothalamin (compounds 85–
92) was carried out using the reaction sequence depicted below
(Scheme 4). Triethyl phosphonoacetate was used to homologate
commercially available aldehydes 54–60 by the Horner–Wads-
worth–Emmons reaction, followed by reduction with DIBAL-H
and oxidation with IBX, leading to the corresponding a,b-unsatu-
rated aldehydes 61–62, 64–68 in 50–90% yields. The ﬁnal steps in
3638 R. C. Barcelos et al. / Bioorg. Med. Chem. 20 (2012) 3635–3651the preparation of goniothalamin analogues 85–92 involved the
addition of the allyl Grignard reagent to the corresponding alde-
hyde, followed by esteriﬁcation of the resulting alcohol with acry-
loyl chloride and ring-closing metathesis reaction employing
Grubbs’ ﬁrst generation catalyst. Overall yields ranged from 15–
70% and the goniothalamin analogues 85–92, as well as the cor-
responding intermediates, were puriﬁed by column chromatogra-
phy on silica gel and characterized by IR, NMR and HRMS
analyses.
The aza-goniothalamin series (compounds 103–111) were
achieved from the corresponding amides (Scheme 5) obtained
according to the methodology described by Hart et al.28 This scaf-
fold was derived from reaction between the unsaturated aldehyde
and a solution of lithium hexamethyldisilazide (LHMDS) in THF at
0 C, followed by the addition of an allylmagnesium bromide solu-
tion leading to a primary amine. This crude product was dissolved
in dichloromethane and treated with acryloyl chloride in the pres-
ence of triethylamine to afford amides 94–102, in 50–87% yields.CHO
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Scheme 4. Synthesis of compounds 85–92. Reagents and conditions: (a) NaH (1.5 equiv
54–60, (b) CH2Cl2, 78 C, DIBAL-H (2.5 equiv), 30 min, (c) IBX (3.0 equiv), 80 C, 3.5 h,
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Scheme 3. Synthesis of compounds 51–53. Reagents and conditions: (a) DDQ (1.7 e
trimethylsilyl bromide (4.4 equiv), pyridine (5.0 equiv), CH2Cl2, 0 C, 30 min (81% yield).
2.5 h (92% yield).Finally, the aza-goniothalamin analogues 103–111 were achieved
by reacting the amides 94–102 with Grubbs’ second generation
catalyst (2 mol %). Overall yields for 103–111 ranged from 20–
70%. The aza-goniothalamin derivatives, as well as the correspond-
ing intermediates, were puriﬁed by column chromatography on
silica gel and characterized by IR, NMR and HRMS analyses.
2.2. Biological activities
Considering that different cell lines display different sensitivi-
ties toward the same cytotoxic compound, the antiproliferative
activity of all the goniothalamin analogues were evaluated
in vitro against seven different human cancer cell lines (U251—gli-
oma; MCF-7—breast; NCI-ADR/RES—breast expressing the multi-
drug resistance phenotype; 786-0—kidney; NCI-H460—lung non-
small cells; OVCAR-03—ovary and HT-29—colon). The cytotoxic
activity of each compound was also evaluated in vitro against
spontaneously transformed keratinocytes from histologicallyCHO
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Scheme 5. Synthesis of compounds 103–111. Reagents and conditions: (a) LHMDS (1.2 equiv), THF, 0 C, aldehydes 61–68, 93, then allylmagnesium bromide (1.2 equiv),
30 min, (b) CH2Cl2, 0 C, Et3N (2.0 equiv), acryloyl chloride (1.5 equiv), then rt, 1 h, (c) amides 94–102, CH2Cl2, reﬂux, Grubbs’ second generation catalyst (2 mol %), 6 h.
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tive control and goniothalamin was included as the reference
compound.
Cell proliferation was determined spectrophotometrically using
sulforhodamine B (SRB) as protein-binding dye and analyses were
based on the U.S. National Cancer Institute (NCI) 60 human tumour
cell line anticancer drug screen (NCI60).29 Differently from other
methods, in the SRB assay measurement of the cell population den-
sity at time zero (the time at which drugs are added) is possible,
which allows the calculation of the cellular responses for total
growth inhibition. The drug concentration resulting in total growth
inhibition (TGI) is calculated from T = T0, where the amount of pro-
tein at the end of drug incubation (T) is equal to the amount at the
beginning (T0).29a
Goniothalamin (1) and its analogues were employed at concen-
trations between 0.25 and 250 lg/mL and doxorubicin at 0.025–
25 lg/mL. Concentration that elicits total growth inhibition (TGI)
was determined after 48 h of cell treatment. The initial in vitro
screening evaluations were planned to select the best candidates
for anticancer drug development in animal models and, eventually,
in clinical trials. To identify compounds with growth-inhibitory or
toxic effects on particular tumour types, it is important to charac-
terize the disease-oriented concept.29b
The biological evaluation of dihydro-c-pyrones 41–46, 50, 52
and 53 and c-pyrones 47–49 and 51 (Fig. 3) are summarized in Ta-
ble 1, which displays the total growth inhibition concentration
(TGI) value for each compound.
In general, the dihydro-c-pyrones and c-pyrones evaluated
were shown to be less potent than goniothalamin (1) with c-pyr-
ones being less cytotoxic than the corresponding dihydro-c-pyr-
ones. In particular, c-pyrone 51 did not display any cytotoxic
effect against the cancer cell lines over the range of concentration
employed and c-pyrones 47–49 displayed a clear correlation be-
tween their total growth inhibition (TGI) values and the degree
of methoxylation of the aromatic ring with the dimethoxylated
derivative 49 being the less cytotoxic in this series of compounds.
For the dihydro-c-pyrones series (43–46), there is no clearcut cor-
relation between the degree of oxygenation of the aromatic ring
and the antiproliferative potency of these compounds, the 4-meth-
oxy derivative 43 displaying the largest TGI value in this series.
The reduced antiproliferative activity of dihydro-c-pyrones and
c-pyrones as compared to goniothalamin (1) can be correlated to
the diminished electron acceptor nature of the vinylogous lactone
moiety present in these goniothalamin analogues while the lack of
potency of c-pyrones can be ascribed to the extensive electronic
conjugation with the aromatic ring which is expected to reducethe Michael acceptor nature of the heterocyclic ring, particularly
when the aromatic ring is substituted with electron donating
methoxyl groups.
On the other hand, noteworthy are the superior antiprolifera-
tive properties of the halogenated dihydro-c-pyrones 42, 52 and
53 when compared to the other representatives in this series, a
behavior which is in line with the reasoning that electron with-
drawing groups are beneﬁcial to the antiproliferative activities of
goniothalamin analogues, a pattern that may be worthy to explore
further.
Table 2 features the total growth inhibition values for gonio-
thalamin (1), aza-goniothalamin (103) and their analogues 85–92
and 104–111 (Fig. 4), as well as for doxorubicin.
It is evident from the data shown that the introduction of the
lactam ring signiﬁcantly reduces the antiproliferative activity for
all cancer cell lines evaluated. In fact, aza-goniothalamin (103)
did not display any cytotoxic activity against several cancer cell
lines and human keratinocytes (HaCat) cells. This pattern is even
more pronounced when we compare the cytotoxic activity of the
methoxy derivatives in both series: all aza-goniothalamin
analogues investigated were not cytotoxic against the cell lines
evaluated except for the 3,5-dimethoxy derivative 109 which only
displayed cytotoxic activity at the largest concentration employed
in the assay. The only aza-goniothalamin derivative deserving fur-
ther investigation seems to be the triﬂuoromethylated analogue
104 wihich displayed promising TGI values for breast cancer
expressing the multidrug resistance phenotype (NCI-ADR/RES)
and glioma (U251) cells (40.6 and 69.9 lM, respectively).
In contrast to the aza-goniothalamin series, the methoxylation
of the aromatic ring proved to be beneﬁcial for the in vitro antipro-
liferative activity of the goniothalamin analogues. While the 3,4,5-
trimethoxy goniothalamin 91 was less potent than goniothalamin
(1) for all the cell lines evaluated, the 3,5-dimethoxy and the 2,4,5-
trimethoxy analogues 90 and 92, respectively, displayed lower TGI
values for most of the cell lines tested while 2,4-dimethoxy gonio-
thalamin 88 proved to be more potent than goniothalamin against
all cancer cell lines. Lower TGI values than doxorubicin were ob-
served for 2,4-dimethoxy goniothalamin 88 against breast cancer
expressing the multidrug resistance phenotype (NCI-ADR/RES),
ovary (OVCAR-03) and colon (HT-29) in addition to be less toxic
to human keratinocytes (HaCat).
3. Conclusions
As compared to our previous study,2b the present work shed
new light on the SAR for goniothalamin analogues regarding the
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Figure 3. Structures of dihydro-c-pyrones 41–46, 50, 52 and 53, c-pyrones 47–49 and 51 and the lead compound goniothalamin (1).
Table 1
TGI values, given in lM, for compounds 1, 41–53 and doxorubicin (DOX) necessary for total inhibition of tumor cell proliferationa
TGI U251 MCF7 NCI-ADR 786-0 NCI-H460 OVCAR-03 HT-29 HaCat
DOXb 2.4 3.7 13.5 2.1 1.3 6.3 7.1 0.8
1 13.7 12.7 8.0 14.8 13.6 14.2 13.9 27.7
41 121.8 152.6 105.3 138.2 82.4 58.2 123.6 126.5
42 38.6 41.2 51.6 39.6 95.6 58.2 33.3 122.8
43 151.9 155.5 239.3 191.5 149.4 87.4 203.9 144.5
44 86.9 130.2 145.8 145.1 89.6 74.3 123.2 133.5
45 101.8 149.4 223.2 125.0 127.3 85.4 134.5 154.7
46 77.0 81.4 186.8 104.1 147.4 101.7 126.9 144.9
47 285.4 691.1 514.2 409.9 508.5 545.5 344.1 710.8
48 278.4 395.9 309.9 376.8 606.1 327.9 379.2 710.0
49 338.9 953.6 407.9 635.4 545.5 540.2 806.7 689.7
50 226.1 172.9 419.6 197.0 192.8 248.6 203.4 264.4
51 >1236.3 >1236.3 >1236.3 >1236.3 >1236.3 >1236.3 >1236.3 >1236.3
52 46.4 42.2 52.9 33.4 117.7 113.5 69.0 164.0
53 24.4 43.2 39.7 27.0 74.6 38.2 24.4 53.3
a Concentration that elicits total growth inhibition (TGI) was determined from non-linear regression analysis using the ORIGIN 7.5 (OriginLab Corporation).
b Doxorubicin (DOX) was the positive control.
3640 R. C. Barcelos et al. / Bioorg. Med. Chem. 20 (2012) 3635–3651prevalence of the a,b-unsaturated d-lactone ring as the pharmaco-
phoric motif for the in vitro antiproliferative activity as compared
to the a,b-unsaturated d-lactam, dihydro-c-pyrone and the c-pyr-
one motifs.
When compared to the 4-methoxy analogue 87, the 2,4-dime-
thoxy derivative 88 displayed higher potency against all the seven
human cancer cell lines investigated, as well as the 3,5-dimethoxy
analogue 90. As to the trimethoxylated series of compounds, the
2,4,5-trimethoxy analogue 92 proved to be more potent than the
monosubstituted derivative 87 and displayed higher antiprolifera-
tive activity than the 3,4,5-trimethoxy analogue 91. Additionally,
the 2,4-dimethoxy goniothalamin 88was shown to be more potent
than goniothalamin (1) against all cancer cell lines evaluated and
more potent than doxorubicin against NCI-ADR/RES, OVCAR-03
and HT-29 while being less toxic to human keratinocytes (HaCat).
The 3,5-dimethoxy and the 2,4,5-trimethoxy analogues 90 and 92
also displayed promising antiproliferative activity when compared
to goniothalamin (1).It seems that the beneﬁcial effect of the methoxy groups at-
tached to the aromatic ring in goniothalamin derivatives investi-
gated could be judiciously explored in the future design of novel
series of analogues as well it can be coupled to the effect of halogen
substituents at C-a of the a,b-unsaturated d-lactone ring, following
the results observed for dihydro-c-pyrones 52 and 53, in the de-
sign of novel and more potent analogues for further studies.
4. General procedures
Reagents and solvents were commercial grade and were used as
supplied, except when speciﬁed in the experimental procedure.
Grubbs’ ﬁrst generation catalyst (Lot#MKBF1581 V) and Grubbs’
second generation catalyst (Lot#MKBG2090 V) were purchased
from Aldrich. Doxorubicin was purchased from Europharma.
Racemic goniothalamin (1) was prepared according to previously
described methodology, except for the utilization of allylmagne-
sium bromide in substitution to the enantioselective allylation
Table 2
TGI values, given in lM, for compounds 1, 85–92, 104–111 and doxorubicin (DOX) necessary for total inhibition of tumor cell proliferationa
TGI U251 MCF7 NCI-ADR 786-0 NCI-H460 OVCAR-03 HT-29 HaCat
Doxb 2.4 3.7 13.5 2.1 1.3 6.3 7.1 0.8
1 13.7 12.7 8.0 14.8 13.6 14.2 13.9 27.7
103 797.6 607.4 966.6 >1254.8 928.5 >1254.8 1195.8 >1254.8
85 43.4 50.4 75.5 52.3 241.5 295.6 71.7 82.7
104 69.9 120.2 40.6 123.4 194.7 329.3 195.4 249.1
86 36.8 51.0 54.8 44.5 476.9 167.2 36.2 69.7
105 130.3 149.5 71.8 127.8 150.4 126.0 139.2 173.7
87 20.6 25.5 17.3 21.6 28.3 61.5 33.7 58.8
106 981.3 >1090.4 841.7 >1090.4 >1090.4 786.8 >1090.4 >1090.4
88 4.6 5.4 8.8 4.1 6.0 5.6 6.6 15.8
107 >964.1 >964.1 >964.1 >964.1 >964.1 >964.1 >964.1 >964.1
89 23.9 7.8 11.6 10.9 14.6 16.8 17.2 63.0
108 >964.1 >964.1 >964.1 >964.1 >964.1 >964.1 >964.1 >964.1
90 8.1 9.5 8.9 10.6 9.0 19.1 8.2 8.8
109 169.9 146.4 203.2 173.4 145.5 232.1 196.6 211.9
91 25.1 15.3 35.1 18.5 28.8 44.9 18.8 21.6
110 >864.1 >864.1 >864.1 >864.1 >864.1 >864.1 >864.1 >864.1
92 11.5 3.8 9.4 6.0 9.8 7.2 15.9 46.9
111 >864.1 >864.1 >864.1 >864.1 >864.1 >864.1 >864.1 >864.1
a Concentration that elicits total growth inhibition (TGI) was determined from non-linear regression analysis using the ORIGIN 7.5 (OriginLab Corporation).
b Doxorubicin (DOX) was the positive control.
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R. C. Barcelos et al. / Bioorg. Med. Chem. 20 (2012) 3635–3651 3641step.2a,b Et3N and CH2Cl2 were distilled from calcium hydride and
THF, ether and benzene were distilled from Na/benzophenone.
Reactions were monitored by TLC analysis using Merck Silica Gel60 F-254 thin layer plates. Flash column chromatography was per-
formed on Acros silica gel 60, 0.040–0.063 mm. 1H NMR and 13C
NMR data were recorded on a Varian Inova (500 MHz for 1H and
3642 R. C. Barcelos et al. / Bioorg. Med. Chem. 20 (2012) 3635–3651125 MHz for 13C NMR) or Bruker Avance (250 MHz for 1H and
62.5 MHz for 13C NMR) spectrometer using as internal standard
the residual nondeuterated solvent (CHCl3) or TMS (1H NMR). Data
are reported as follows: chemical shift in ppm (d), multiplicity
(s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet,
m = multiplet, br = broad signal, app = apparent signal), coupling
constant (Hz), integration. High resolution mass spectra (HRMS)
for novel compoundsweremeasured on aWatersXEVOQ-TOF spec-
trometer (ESI) or in a Waters GCT Premier (EI). Infrared spectra (IR)
were obtained on aABBBomemMBSeries B102, Thermo-Nicolet IR-
200 or iS5 spectrometer and absorptions are reported in reciprocal
centimeters. Melting points were recorded on an Electrothermal
9100 melting point apparatus and were uncorrected.
4.1. Experimental procedures
4.1.1. 2-Vinyl-2H-pyran-4(3H)-one (40)
To a solution of acrolein (38, 42.4 mmol, 2.83 mL) in anhydrous
diethyl ether (160 mL) under nitrogen atmosphere at 78 C was
added trans-1-methoxy-3-trimethylsiloxy-1,3-butadiene (37,
15.3 mmol, 2.64 g), followed by 1.3 equiv of boron triﬂuoride
etherate (20.3 mmol; 2.51 mL). After 3.0 h, a saturated aqueous
solution of sodium bicarbonate (100 mL) was added, the layers
were separated and the aqueous layer was extracted with diethyl
ether (3  100 mL). The combined organic layers were dried over
anhydrous magnesium sulfate, ﬁltered and concentrated under re-
duced pressure. The crude product was dissolved in CH2Cl2
(250 mL) and the resulting solution was cooled to 0 C. Triﬂuoro-
acetic acid (22.0 mmol; 1.7 mL; 1.3 equiv) was added and the
resulting solution was maintained under magnetic stirring and at
room temperature for 40 min. The solvent was removed under re-
duced pressure and the residue was dissolved in diethyl ether
(100 mL) and washed with a saturated aqueous solution of sodium
hydrogen carbonate (100 mL). The aqueous layer was extracted
with diethyl ether (2  100 mL) and the combined organic layers
were dried over magnesium sulfate, ﬁltered and concentrated un-
der vacuum. The residue was puriﬁed by ﬂash column chromatog-
raphy (hexanes/ethyl acetate 2:1 v/v) giving the desired dihydro-c-
pyrone 40 in 70% yield (1.33 g), as a light yellow oil. IR (cm1, thin
ﬁlm): 1678, 1594, 1405, 1273, 1225, 1039, 993, 937, 895, 795; 1H
NMR (250 MHz, CDCl3): d 7.38 (d, J = 6.0 Hz, 1H), 5.95 (ddd,
J = 16.6, 10.6 and 5.8 Hz, 1H), 5.45 (s, 1H), 5.38 (dd, J = 16.6 and
12.2 Hz, 2H), 4.98–4.85 (m, 1H), 2.71–2.49 (m, 2H); 13C NMR
(62.5 MHz, CDCl3): d 191.3 (C0), 162.5 (CH), 134.1 (CH), 117.9
(CH2), 106.9 (CH), 79.1 (CH), 41.1 (CH2).
4.1.2. General procedure for the oleﬁn cross-metathesis reaction
A typical procedure for the preparation of dihydro-c-pyrones
41–46 follows: to a solution of dihydro-c-pyrone 40 (0.5 mmol;
62.0 mg) in anhydrous CH2Cl2 (9 mL) was added the corresponding
styrene (3–5 equiv), Grubbs’ second generation catalyst (8.5 mg;
2 mol %) and copper iodide (2.9 mg; 3 mol %), under nitrogen
atmosphere. The reaction mixture was immersed in an oil bath
and heated at reﬂux until TLC analysis indicated complete con-
sumption of the starting material (3–6 h). After cooling to room
temperature, 50 equiv of DMSO (relative to the catalyst) were
added and the mixture was maintained under magnetic stirring
overnight. The solvent was then removed under reduced pressure
and the residue was puriﬁed by ﬂash column chromatography
(using the eluent indicated) to afford the corresponding cross-
metathesis adducts 41–46.
4.1.2.1. (E)-2-Styryl-2H-pyran-4(3H)-one (41). Prepared
according to the general procedure for the oleﬁn cross-metathesis
reaction in 79% yield (light brown viscous oil). Eluent: hexanes/
ethyl acetate 2:1, 1:1 v/v. IR (cm1, thin ﬁlm): 2925, 2855, 1676,1594, 1452, 1406, 1268, 1219, 1038, 969, 741; 1H NMR
(250 MHz, CDCl3): d 7.47–7.25 (m, 6H), 6.73 (d, J = 16.0 Hz, 1H),
6.31 (dd, J = 16.0 and 6.5 Hz, 1H), 5.46 (d, J = 6.0 Hz, 1H), 5.11–
5.02 (m, 1H), 2.73 (dd, J = 16.8 and 12.4 Hz, 1H), 2.60 (dd, J = 16.8
and 4.4 Hz, 1H); 13C NMR (62.5 MHz, CDCl3): d 191.8 (C0), 162.9
(CH), 135.5 (C0), 133.7 (CH), 128.6 (2  CH), 128.5 (CH), 126.7
(2  CH), 125.0 (CH), 107.2 (CH), 79.6 (CH), 41.9 (CH2); HRMS
(ESI+) m/z: Calcd for C13H13O2 [M+H+] 201.0916, found 201.0903.
4.1.2.2. (E)-2-(4-(Triﬂuoromethyl)styryl)-2H-pyran-4(3H)-one
(42). Prepared according to the general procedure for the ole-
ﬁn cross-metathesis reaction in 58% yield (light yellow solid). Elu-
ent: hexanes/ethyl acetate 1:1 v/v. Mp: 43.0–44.4 C; IR (cm1,
thin ﬁlm): 1678, 1596, 1408, 1325, 1269, 1220, 1165, 1121,
1067, 1039, 973; 1H NMR (250 MHz, CDCl3): d 7.60 (d, J = 8.3 Hz,
2H), 7.50 (d, J = 8.3 Hz, 2H), 7.42 (d, J = 6.0 Hz, 1H), 6.76 (d,
J = 16.0 Hz, 1H), 6.39 (dd, J = 16.0 and 6.1 Hz, 1H), 5.49 (dd, J = 6.0
and 0.6 Hz, 1H), 5.15–5.06 (m, 1H), 2.81–2.56 (m, 2H); 13C NMR
(62.5 MHz, CDCl3): d 191.4 (C0), 162.7 (CH), 139.1 (C0), 131.9
(CH), 130.2 (q, J = 32.4 Hz, C0), 127.7 (CH), 126.9 (2  CH), 125.7
(q, J = 15.1 Hz, 2  CH), 124.0 (q, J, = 270.0 Hz, C0), 107.5 (CH),
79.1 (CH), 41.7 (CH2); HRMS (ESI+) m/z: Calcd for C14H12F3O2
[M+H+] 269.0789, found 269.0838.
4.1.2.3. (E)-2-(4-Methoxystyryl)-2H-pyran-4(3H)-one (43).
Prepared according to the general procedure for the oleﬁn cross-
metathesis reaction in 73% yield (light yellow solid). Eluent: hex-
anes/ethyl acetate 2:1 v/v. Mp: 79.0–80.0 C; IR (cm1, thin ﬁlm):
2928, 1673, 1594, 1513, 1463, 1405, 1251, 1219, 1177, 1034,
970, 835, 792; 1H NMR (250 MHz, CDCl3): d 7.39 (d, J = 6.0 Hz,
1H), 7.34 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 6.65 (d,
J = 16.0 Hz, 1H), 6.15 (dd, J = 16.0 and 6.8 Hz, 1H), 5.45 (d,
J = 6.0 Hz, 1H), 5.08–4.98 (m, 1H), 3.80 (s, 3H), 2.72 (dd, J = 16.8
and 12.6 Hz, 1H), 2.59 (dd, J = 16.8 and 4.1 Hz, 1H); 13C NMR
(62.5 MHz, CDCl3): d 192.0 (C0), 163.0 (CH), 159.9 (C0), 133.5
(CH), 128.2 (C0), 128.0 (2  CH), 122.7 (CH), 114.1 (2  CH), 107.2
(CH), 80.0 (CH), 55.2 (OCH3), 42.0 (CH2); HRMS (ESI+) m/z: Calcd
for C14H15O3 [M+H+] 231.1021, found 231.1062.
4.1.2.4. (E)-2-(3,4-Dimethoxystyryl)-2H-pyran-4(3H)-one (44).
Prepared according to the general procedure for the oleﬁn cross-
metathesis reaction in 56% yield (light yellow viscous oil). Eluent:
CH2Cl2/ethyl acetate 95:05 v/v, then hexanes/ethyl acetate 1:1 v/v.
IR (cm1, thin ﬁlm): 1671, 1593, 1515, 1463, 1406, 1263, 1140,
1027, 970, 794; 1H NMR (250 MHz, CDCl3): d 7.40 (d, J = 6.0 Hz,
1H), 6.95–6.81 (m, 3H), 6.65 (d, J = 15.9 Hz, 1H), 6.16 (dd, J = 15.9
and 6.8 Hz, 1H), 5.46 (d, J = 6.0 Hz, 1H), 5.09–5.00 (m, 1H), 3.90
(s, 3H), 3.88 (s, 3H), 2.74 (dd, J = 16.7 and 12.5 Hz, 1H), 2.59 (dd,
J = 16.7 and 4.2 Hz, 1H); 13C NMR (62.5 MHz, CDCl3): d 191.9 (C0),
162.9 (CH), 149.5 (C0), 149.1 (C0), 133.7 (CH), 128.5 (C0), 122.9
(CH), 120.3 (CH), 111.0 (CH), 108.9 (CH), 107.2 (CH), 79.8 (CH),
55.8 (2  OCH3), 42.0 (CH2); HRMS (ESI+) m/z: Calcd for C15H17O4
[M+H+] 261.1127, found 261.1207.
4.1.2.5. (E)-2-(3,4,5-Trimethoxystyryl)-2H-pyran-4(3H)-one (45).
Prepared according to the general procedure for the oleﬁn cross-
metathesis reaction in 67% yield (light yellow solid). Eluent:
CH2Cl2/ethyl acetate 95:05 v/v, then hexanes/ethyl acetate 1:1 v/
v. Mp: 128.0–130.0 C; IR (cm1, thin ﬁlm): 2928, 1663, 1592,
1507, 1423, 1402, 1334, 1248, 1237, 1124, 1038, 1008, 982, 795;
1H NMR (500 MHz, CDCl3): d 7.41 (d, J = 6.0 Hz, 1H), 6.65 (d,
J = 15.7 Hz, 1H), 6.64 (s, 2H), 6.22 (dd, J = 15.9 and 6.5 Hz, 1H),
5.47 (d, J = 6.0 Hz, 1H), 5.12–5.02 (m, 1H), 3.88 (s, 6H), 3.86 (s,
3H), 2.75 (dd, J = 16.8 and 12.2 Hz, 1H), 2.62 (dd, J = 16.8 and
4.5 Hz, 1H); 13C NMR (125 MHz, CDCl3): d 191.7 (C0), 162.8 (CH),
153.3 (C0), 138.5 (C0), 133.7 (2  CH), 131.2 (C0), 124.4 (CH),
R. C. Barcelos et al. / Bioorg. Med. Chem. 20 (2012) 3635–3651 3643107.2 (CH), 103.8 (CH), 79.5 (CH), 60.8 (OCH3), 56.1 (2  OCH3),
41.9 (CH2); HRMS (ESI+) m/z: Calcd for C16H19O5 [M+H+]
291.1232, found 291.1327.
4.1.2.6. (E)-2-(2-(Benzo[d][1,3]dioxol-5-yl)vinyl)-2H-pyran-
4(3H)-one (46). Prepared according to the general procedure
for the oleﬁn cross-metathesis reaction in 64% yield (light yellow
solid). Eluent: CH2Cl2/ethyl acetate 95:05 v/v, then hexanes/ethyl
acetate 1:1 v/v. Mp: 111.2–112.2 C; IR (cm1, thin ﬁlm): 2917,
1666, 1592, 1503, 1449, 1257, 1225, 1191, 1037, 974, 927, 906,
791; 1H NMR (250 MHz, CDCl3): d 7.40 (d, J = 6.0 Hz, 1H), 6.94 (d,
J = 1.5 Hz, 1H), 6.85 (dd, J = 8.0 and 1.5 Hz, 1H), 6.77 (d, J = 8.0 Hz,
1H), 6.62 (d, J = 15.9 Hz, 1H), 6.12 (dd, J = 15.9 and 6.7 Hz, 1H),
5.97 (s, 2H), 5.46 (d, J = 6.0 Hz, 1H), 5.09–4.97 (m, 1H), 2.72 (dd,
J = 16.8 and 12.5 Hz, 1H), 2.59 (dd, J = 16.8 and 4.4 Hz, 1H); 13C
NMR (62.5 MHz, CDCl3): d 191.8 (C0), 162.9 (CH), 148.1 (C0),
148.0 (C0), 133.5 (CH), 129.9 (C0), 123.1 (CH), 121.8 (CH), 108.3
(CH), 107.2 (CH), 105.8 (CH), 101.2 (CH2), 79.8 (CH), 42.0 (CH2);
HRMS (ESI+) m/z: Calcd for C14H13O4 [M+H+] 245.0808, found
245.0817.
4.1.3. General procedure for the DDQ oxidation of dihydro-
c-pyrones
To a solution of the dihydro-c-pyrone 41, 43, 44 or 50
(0.25 mmol) in dry benzene (3.0 mL), under nitrogen atmosphere
and magnetic stirring, was added DDQ (1.7 equiv; 0.43 mmol;
96.5 mg) and the reaction mixture was heated to reﬂux for 3–
15 h. After cooling to room temperature, the reaction mixture
was diluted with CH2Cl2 (30 mL), washed with a saturated aqueous
solution of sodium hydrogen carbonate (20 mL). The aqueous layer
was extracted with CH2Cl2 (2  30 mL) and the combined organic
layers were dried over magnesium sulfate, ﬁltered and concen-
trated under reduced pressure. The crude was puriﬁed by ﬂash col-
umn chromatography (using the eluent indicated) to provide the
corresponding c-pyrones 47–49 or 51 .
4.1.3.1. (E)-2-Styryl-4H-pyran-4-one (47). Prepared accord-
ing to the general procedure for oxidation with DDQ in 85% yield
(white solid). Eluent: hexanes/ethyl acetate 2:1, 1:1, 1:3 v/v. Mp:
83.8–85.0 C; IR (cm1, thin ﬁlm): 2927, 1646, 1596, 1411, 1381,
1260, 1171, 973, 945, 874, 851, 759, 695; 1H NMR (500 MHz,
CDCl3): d 7.73 (d, J = 3.0 Hz, 1H), 6.66 (dd, J = 4.1 and 0.8 Hz, 2H),
7.42–7.33 (m, 4H), 6.66 (d, J = 8.1 Hz, 1H), 6.31–6.27 (m, 2H); 13C
NMR (62.5 MHz, CDCl3): d 179.2 (C0), 162.2 (C0), 154.4 (CH),
136.2 (CH), 134.8 (C0), 129.7 (CH), 128.9 (2  CH), 127.5
(2  CH), 119.4 (CH), 116.8 (CH), 114.9 (CH); HRMS (ESI+) m/z:
Calcd for C13H11O2 [M+H+] 199.0759, found 199.0820.
4.1.3.2. (E)-2-(4-Methoxystyryl)-4H-pyran-4-one (48). Pre-
pared according to the general procedure for oxidation with DDQ
in 78% yield (off-white solid). Eluent: ethyl acetate. Mp: 123.4–
124.0 C; IR (cm1, thin ﬁlm): 3060, 2919, 2848, 1652, 1599,
1515, 1411, 1383, 1264, 1252, 1165, 1018, 970, 949, 859, 847,
810; 1H NMR (250 MHz, CDCl3): d 7.70 (d, J = 5.7 Hz, 1H), 7.44 (d,
J = 8.7 Hz, 2H), 7.32 (d, J = 16.0 Hz, 1H), 6.90 (d, J = 8.7 Hz, 2H),
6.51 (d, J = 16.0 Hz, 1H), 6.31–6.19 (m, 2H), 3.82 (s, 3H); 13C NMR
(62.5 MHz, CDCl3): d 179.2 (C0), 162.6 (C0), 160.9 (C0), 154.2 (CH),
135.8 (CH), 129.0 (2  CH), 127.5 (C0), 117.0 (CH), 116.6 (CH),
114.3 (2  CH), 114.1 (CH), 55.3 (OCH3); HRMS (ESI+) m/z: Calcd
for C14H13O3 [M+H+] 229.0865, found 229.0879.
4.1.3.3. (E)-2-(3,4-Dimethoxystyryl)-4H-pyran-4-one (49).
Prepared according to the general procedure for oxidation with
DDQ in 85% yield (off-white solid). Eluent: ethyl acetate + 2%
MeOH v/v. Mp: 133.5–134.6 C; IR (cm1, thin ﬁlm): 2918, 1647,
1596, 1508, 1412, 1380, 1263, 1156, 1140, 1019, 966, 942, 862,800, 769; 1H NMR (250 MHz, CDCl3): d 7.71 (d, J = 5.5 Hz, 1H),
7.32 (d, J = 16.0 Hz, 1H), 7.07 (d, J = 8.3 Hz, 1H), 7.03 (s, 1H), 6.86
(d, J = 8.2 Hz, 1H), 6.52 (d, J = 16.0 Hz, 1H), 6.30–6.20 (m, 2H),
3.92 (s, 3H), 3.90 (s, 3H); 13C NMR (62.5 MHz, CDCl3): d 179.2
(C0), 162.5 (C0), 154.2 (CH), 150.7 (C0), 149.2 (C0), 136.1 (CH),
127.8 (C0), 121.9 (CH), 117.2 (CH), 116.6 (CH), 114.2 (CH), 111.2
(CH), 109.2 (CH), 55.9 (2  OCH3); HRMS (ESI+) m/z: Calcd for
C15H15O4 [M+H+] 259.0970, found 259.1017.
4.1.3.4. 2-(4-Methoxyphenyl)-4H-pyran-4-one (51). Pre-
pared according to the general procedure for oxidation with DDQ
in 87% yield (light yellow solid). Eluent: CH2Cl2/ethyl acetate 1:2
v/v). Mp: 123.0–125.0 C; IR (cm1, thin ﬁlm): 2919, 2838, 1644,
1594, 1512, 1430, 1365, 1307, 1262, 1233, 1181, 1017, 930, 815,
645; 1H NMR (250 MHz, CDCl3): d 7.78 (d, J = 5.8 Hz, 1H), 7.67 (d,
J = 8.9 Hz, 2H), 6.95 (d, J = 8.9 Hz, 2H), 6.66 (d, J = 2.4 Hz, 1H),
6.31 (dd, J = 5.8 and 2.4 Hz, 1H), 3.84 (s, 3H); 13C NMR
(62.5 MHz, CDCl3): d 179.1 (C0), 163.9 (C0), 162.1 (C0), 154.5
(CH), 127.3 (2  CH), 123.3 (C0), 116.7 (CH), 114.3 (2  CH),
110.7 (CH), 55.3 (OCH3); HRMS (ESI+) m/z: Calcd for C12H11O3
[M+H+] 203.0708, found 203.0797.
4.1.4. 5-Bromo-2-(4-methoxyphenyl)-2H-pyran-4(3H)-one (52)
Iodosobenzene diacetate (2.2 equiv; 1.14 mmol; 368 mg) was
suspended in anhydrous CH2Cl2 (2.6 mL) and cooled under mag-
netic stirring to 0 C, under nitrogen atmosphere. Trimethylsilyl
bromide (4.4 equiv; 2.29 mmol; 302 lL) was then added dropwise
and the resulting orange colored solution stirred at this tempera-
ture for 45 min. Freshly distilled pyridine (5.0 equiv; 2.6 mmol;
210 lL) was added, followed by a solution of dihydro-c-pyrone
50 (0.52 mmol; 106 mg) in anhydrous CH2Cl2 (2.6 mL). The resul-
tant reaction mixture was maintained under these conditions for
ca. 30 min. After this period, the reaction was quenched with a sat-
urated aqueous solution of sodium thiosulfate (2.0 mL) and parti-
tioned between a saturated solution of aqueous sodium
hydrogen carbonate (20 mL) and CH2Cl2 (3  20 mL). The com-
bined organic layers were dried over magnesium sulfate, ﬁltered
and concentrated under reduced pressure. The residue was puri-
ﬁed by ﬂash column chromatography (hexanes/ethyl acetate 4:1,
3:1 v/v) to afford the desired 3-bromo-dihydro-c-pyrone 52 in
81% yield (119 mg), as a light yellow solid. Mp: 108.2–108.9 C;
IR (cm1, thin ﬁlm): 3039, 2919, 1667, 1617, 1567, 1519, 1357,
1260, 1181, 1128, 1029, 996, 818; 1H NMR (250 MHz, CDCl3, d):
7.79 (s, 1H), 7.33 (d, J = 8.7 Hz, 2H), 6.95 (d, J = 8.7 Hz, 2H), 5.49
(dd, J = 14.1 and 3.6 Hz, 1H), 3.84 (s, 3H), 3.09 (dd, J = 16.9 and
14.1 Hz, 1H), 2.90 (dd, J = 16.9 and 3.6 Hz, 1H); 13C NMR
(62.5 MHz, CDCl3): d 185.0 (C0), 161.9 (CH), 160.3 (C0), 128.6 (C0),
127.8 (2  CH), 114.2 (2  CH), 102.4 (C0), 81.7 (CH), 55.3 (OCH3),
43.0 (CH2); HRMS (ESI+) m/z: Calcd for C12H12BrO3 [M+H+]
282.9964, found 283.0009.
4.1.5. 5-Iodo-2-(4-methoxyphenyl)-2H-pyran-4(3H)-one (53)
To a solution of molecular iodine (2.25 equiv; 4.73 mmol; 1.2 g)
in anhydrous CH2Cl2 (11 mL) at 0 C, under magnetic stirring and
nitrogen atmosphere, was added freshly distilled pyridine
(5.0 equiv; 23.7 mmol; 0.8 mL). A solution of dihydro-c-pyrone
50 (2.10 mmol; 430 mg) in anhydrous CH2Cl2 (11 mL) was then
added dropwise. The resultant reaction mixture was maintained
under magnetic stirring at 0 C for 30 min and then at room tem-
perature for ca. 2.5 h. After this period, the reaction was quenched
with a saturated aqueous solution of sodium thiosulfate (20 mL)
and partitioned between a saturated solution of aqueous sodium
hydrogen carbonate (50 mL) and CH2Cl2 (3  70 mL). The com-
bined organic layers were dried over sodium sulfate, ﬁltered and
concentrated under reduced pressure. The residue was puriﬁed
by ﬂash column chromatography (hexanes/ethyl acetate 2:1 v/v)
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(0.64 g), as a light yellow solid. Mp: 113.6–114.2 C; IR (cm1, thin
ﬁlm): 1660, 1612, 1552, 1516, 1342, 1273, 1250, 1175, 1119, 1102,
1022, 987, 951, 815; 1H NMR (250 MHz, CDCl3): d 7.88 (s, 1H), 7.32
(d, J = 8.6 Hz, 2H), 6.95 (d, J = 8.6 Hz, 2H), 5.51 (dd, J = 13.7 and
4.0 Hz, 1H), 3.83 (s, 3H), 3.11 (dd, J = 16.8 and 13.7 Hz, 1H), 2.97
(dd, J = 16.8 and 4.0 Hz, 1H); 13C NMR (62.5 MHz, CDCl3): d 186.2
(C0), 166.0 (CH), 160.3 (C0), 128.7 (C0), 127.8 (2  CH), 114.3
(2  CH), 81.7 (CH), 76.8 (C0), 55.3 (OCH3), 42.5 (CH2); HRMS
(ESI+) m/z: Calcd for C12H12IO3 [M+H+] 330.9826, found 330.9882.
4.1.6. General procedure for the aldehyde homologations
To a suspension of sodium hydride 60% in mineral oil
(1.5 equiv; 18.1 mmol) in a mixture of anhydrous THF (50 mL)
and anhydrous DMF (4 mL), under nitrogen atmosphere and cooled
at 0 C, was added triethyl phosphonoacetate (1.3 equiv;
15.6 mmol). The reaction mixture was maintained under magnetic
stirring under these conditions for 15 min. A solution of aldehyde
54–60 (12.0 mmol) in anhydrous THF (10 mL) was then added
dropwise and the cooling bath was removed. After total consump-
tion of the starting material (TLC analysis), the reaction mixture
was ﬁltered on silica under reduced pressure and the ﬁlter cake
washed with ethyl acetate. The solution was concentrated to dry-
ness under vacuum and the residue was subjected to ﬂash column
chromatography (hexanes/ethyl acetate 2:1, 1:1 v/v or 10:1 v/v in
the case of the CF3-derivatives). The ester intermediate obtained
(10.7 mmol) was dissolved in anhydrous CH2Cl2 (107 mL) and the
resulting solution was cooled to 78 C, under nitrogen atmo-
sphere and magnetic stirring. DIBAL-H (2.5 equiv; 26.8 mmol)
was added dropwise and the reaction mixture was maintained un-
der these conditions until completion, ca. 30 min. After this period,
the temperature was raised to 0 C and ethyl acetate (15 mL) was
added carefully, followed by 1 M HCl (90 mL). The emulsion re-
mained under strong stirring until complete phase separation.
The aqueous layer was extracted with CH2Cl2 (3  50 mL) and
the combined organic layer was dried with anhydrous MgSO4, ﬁl-
tered and concentrated to dryness under reduced pressure. The
residue was puriﬁed by ﬂash column chromatography (hexanes/
ethyl acetate 1:1 v/v or 2:1 v/v in the case of the CF3-derivatives)
and the allylic alcohol obtained (10.7 mmol) was dissolved in ethyl
acetate (77 mL). Next, IBX was added (3.0 equiv; 32.1 mmol) and
the resulting suspension was immersed in an oil bath at 80 C.
After, vigorous stirring under open atmosphere for approximately
3.5 h, the reaction mixture was cooled to room temperature, ﬁl-
tered over Celite under vacuum and the ﬁlter cake washed with
ethyl acetate (3  20 mL). The ﬁltrates were combined and the sol-
vent was removed under reduced pressure. The residue obtained
was puriﬁed by ﬂash column chromatography (hexanes/ethyl ace-
tate 2:1, 1:1 v/v or 3:1 v/v in the case of the CF3-derivatives) to give
the homologated aldehydes 61–62, 64–68.
4.1.6.1. (E)-3-(2-(Triﬂuoromethyl)phenyl)acrylaldehyde (61).
Prepared according to the general procedure for the aldehyde
homologations in 61% yield (yellow solid). Mp: 39.0–41.0 C; IR
(cm1, thin ﬁlm): 3079, 1689, 1631, 1603, 1577, 1489, 1315,
1166, 1122, 1061, 1037, 974, 768; 1H NMR (250 MHz, CDCl3): d
9.68 (d, J = 7.6 Hz, 1H), 7.80 (dd, J = 15.8 and 1.8 Hz, 1H), 7.68 (t,
J = 7.5 Hz, 2H), 7.60–7.40 (m, 2H), 6.62 (dd, J = 15.8 and 7.6 Hz,
1H); 13C NMR (62.5 MHz, CDCl3): d 193.0 (CH), 147.1 (q,
J = 2.0 Hz, CH), 132.5 (q, J = 1.4 Hz, C0), 132.1 (CH), 131.8 (CH),
130.3 (CH), 128.6 (q, J = 30.4 Hz, C0), 127.8 (CH), 126.1 (q,
J = 5.7 Hz, CH), 123.7 (q, J = 274.2 Hz, C0); HRMS (ESI+) m/z: Calcd
for C10H8F3O [M+H+] 201.0527, found 201.0619.
4.1.6.2. (E)-3-(4-(Triﬂuoromethyl)phenyl)acrylaldehyde (62).
Prepared according to the general procedure for the aldehydehomologations in 80% yield (yellow solid). Mp: 59.0–61.0 C; IR
(cm1, thin ﬁlm): 2819, 2721, 1680, 1629, 1574, 1421, 1322,
1171, 1122, 1065, 981, 821, 760; 1H NMR (250 MHz, CDCl3): d
9.75 (d, J = 7.6 Hz, 1H), 7.70–7.67 (m, 4H), 7.51 (d, J = 16.0 Hz,
1H), 6.77 (dd, J = 16.0 and 7.6 Hz, 1H); 13C NMR (62.5 MHz, CDCl3):
d 193.0 (CH), 150.0 (CH), 137.2 (C0), 132.0 (q, J = 32.9 Hz, C0), 130.2
(CH), 128.3 (2  CH), 125.7 (q, J = 3.9 Hz, 2  CH), 123.5 (q,
J = 272.5 Hz, C0); HRMS (ESI+) m/z: Calcd for C10H8F3O [M+H+]
201.0527, found 201.0619.
4.1.6.3. (E)-3-(2,4-Dimethoxyphenyl)acrylaldehyde (64).
Prepared according to the general procedure for the aldehyde
homologations in 61% yield (yellow solid). Mp: 99.0–100.0 C; IR
(cm1, thin ﬁlm): 2970, 2922, 2845, 2767, 1668, 1610, 1573,
1503, 1469, 1455, 1427, 1327, 1278, 1168, 1110, 971, 843, 785;
1H NMR (250 MHz, CDCl3): d 9.59 (d, J = 7.9 Hz, 1H), 7.71 (d,
J = 15.9 Hz, 1H), 7.46 (d, J = 8.6 Hz, 1H), 6.67 (dd, J = 15.9 and
7.9 Hz, 1H), 6.51 (dd, J = 8.6 and 2.3 Hz, 1H), 6.44 (d, J = 2.3 Hz,
1H), 3.86 (s, 3H), 3.83 (s, 3H); 13C NMR (62.5 MHz, CDCl3): d
194.5 (CH), 163.7 (C0), 159.9 (C0), 148.3 (CH), 130.4 (CH), 126.7
(CH), 116.1 (C0), 105.6 (CH), 98.3 (CH), 55.5 (OCH3), 55.4 (OCH3);
HRMS (ESI+) m/z: Calcd for C11H13O3 [M+H+] 193.0865, found
193.0950.
4.1.6.4. (E)-3-(3,4-Dimethoxyphenyl)acrylaldehyde (65).
Prepared according to the general procedure for the aldehyde
homologations in 81% yield (yellow solid). Mp: 80.0–81.5 C; IR
(cm1, thin ﬁlm): 3014, 2974, 2923, 2841, 2806, 2749, 1673,
1621, 1596, 1513, 1421, 1266, 1226, 1138, 1131, 1017, 878, 800,
742; 1H NMR (250 MHz, CDCl3): d 9.66 (d, J = 7.7 Hz, 1H), 7.41 (d,
J = 15.8 Hz, 1H), 7.16 (dd, J = 8.3 and 1.8 Hz, 1H), 7.08 (d,
J = 1.8 Hz, 1H), 6.90 (d, J = 8.3 Hz, 1H), 6.61 (dd, J = 15.8 and
7.7 Hz, 1H), 3.93 (s, 3H), 3.92 (s, 3H); 13C NMR (62.5 MHz, CDCl3):
d 193.3 (CH), 152.7 (CH), 151.8 (C0), 149.2 (C0), 126.9 (C0), 126.5
(CH), 123.3 (CH), 111.0 (CH), 109.8 (CH), 55.8 (OCH3), 55.7
(OCH3); HRMS (ESI+) m/z: Calcd for C11H13O3 [M+H+] 193.0865,
found 193.0866.
4.1.6.5. (E)-3-(3,5-Dimethoxyphenyl)acrylaldehyde (66).
Prepared according to the general procedure for the aldehyde
homologations in 87% yield (yellow solid). Mp: 78.5–80.0 C; IR
(cm1, thin ﬁlm): 3090, 2994, 2968, 2846, 2814, 2730, 1674,
1590, 1446, 1424, 1349, 1299, 1264, 1209, 1193, 1152, 1126,
1058, 970, 832, 819; 1H NMR (250 MHz, CDCl3): d 9.67 (d,
J = 7.7 Hz, 1H), 7.37 (d, J = 15.9 Hz, 1H), 6.68 (d, J = 2.2 Hz, 2H),
6.65 (dd, J = 15.9 and 7.7 Hz, 1H), 6.53 (t, J = 2.2 Hz, 1H), 3.80 (s,
6H); 13C NMR (62.5 MHz, CDCl3): d 193.5 (CH), 161.1 (2  C0),
152.6 (CH), 135.8 (C0), 128.9 (CH), 106.3 (2  CH), 103.3 (CH),
55.4 (2  OCH3); HRMS (ESI+) m/z: Calcd for C11H13O3 [M+H+]
193.0865, found 193.0950.
4.1.6.6. (E)-3-(3,4,5-Trimethoxyphenyl)acrylaldehyde (67).
Prepared according to the general procedure for the aldehyde
homologations in 90% yield (yellow solid). Mp: 110.0–111.0 C;
IR (cm1, thin ﬁlm): 3013, 3002, 2979, 2948, 2840, 2749, 1699,
1677, 1621, 1581, 1504, 1470, 1422, 1335, 1123, 998, 973, 817,
736; 1H NMR (250 MHz, CDCl3): d 9.66 (d, J = 7.7 Hz, 1H), 7.37 (d,
J = 15.8 Hz, 1H), 6.78 (s, 2H), 6.61 (dd, J = 15.8 and 7.7 Hz, 1H),
3.88 (s, 9H); 13C NMR (62.5 MHz, CDCl3): d 193.3 (CH), 153.5
(2  C0), 152.6 (CH), 140.9 (C0), 129.4 (C0), 127.9 (CH), 105.7
(2  CH), 60.9 (OCH3), 56.1 (2  OCH3); HRMS (ESI+) m/z: Calcd
for C12H15O4 [M+H+] 223.0970, found 223.0979.
4.1.6.7. (E)-3-(2,4,5-Trimethoxyphenyl)acrylaldehyde (68).
Prepared according to the general procedure for the aldehyde
homologations in 50% yield (yellow solid). Mp: 129.0–130.5 C;
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1468, 1310, 1277, 1210, 1120, 1025, 876, 828, 751; 1H NMR
(250 MHz, CDCl3): d 9.43 (d, J = 7.8 Hz, 1H), 7.59 (d, J = 15.9 Hz,
1H), 6.82 (s, 1H), 6.44 (dd, J = 15.9 and 7.8 Hz, 1H), 6.33 (s, 1H),
3.75 (s, 3H), 3.71 (s, 3H), 3.67 (s, 3H); 13C NMR (62.5 MHz, CDCl3):
d 193.6 (CH), 153.7 (C0), 152.9 (C0), 147.3 (CH), 142.8 (C0), 125.7
(CH), 113.9 (C0), 110.2 (CH), 96.0 (CH), 55.9 (OCH3), 55.7 (OCH3),
55.5 (OCH3); HRMS (ESI+) m/z: Calcd for C12H15O4 [M+H+]
223.0970, found 223.1012.
4.1.7. General procedure for the allylation reactions
To a stirred solution of the homologated aldehyde 61–68
(4.94 mmol) in anhydrous THF (25 mL), at 78 C under nitrogen
atmosphere, was added dropwise a solution of allylmagnesium
bromide in diethyl ether (1.2 equiv; 5.93 mmol). The reaction mix-
ture was maintained under these conditions for 30 min. After this
period, a saturated aqueous solution of ammonium chloride
(10 mL) was added and the layers were separated. The aqueous
layer was extracted with diethyl ether (3  10 mL) and the com-
bined organic layers were dried over anhydrous MgSO4, ﬁltered
and concentrated under reduced pressure. The crude was puriﬁed
by ﬂash column chromatography (using the eluent indicated) to
give the corresponding homoallylic alcohols 69–76.
4.1.7.1. (E)-1-(2-(Triﬂuoromethyl)phenyl)hexa-1,5-dien-3-ol
(69). Prepared according to the general procedure for the ally-
lation reactions in 90% yield (yellow oil). Eluent: hexanes/ethyl
acetate 4:1 v/v. IR (cm1, thin ﬁlm): 3418, 3078, 2931, 1640,
1614, 1576, 1488, 1455, 1315, 1165, 1123, 1036, 974, 921, 768;
1H NMR (250 MHz, CDCl3): d 7.66–7.57 (m, 2H), 7.50 (t,
J = 7.5 Hz, 1H), 7.39–7.29 (m, 1H), 6.99 (d, J = 15.7 Hz, 1H), 6.21
(dd, J = 15.7 and 6.5 Hz, 1H), 5.95–5.77 (m, 1H), 5.26–5.13 (m,
2H), 4.46–4.35 (m, 1H), 2.54–2.32 (m, 2H), 1.83 (d, J = 4.1 Hz,
1H); 13C NMR (62.5 MHz, CDCl3): d 136.0 (CH), 135.9 (C0), 133.7
(CH), 131.8 (CH), 127.5 (CH), 127.4 (q, J = 30.0 Hz, C0), 127.3 (CH),
126.3 (q, J = 1.8 Hz, CH), 125.7 (q, J = 5.7 Hz, CH), 124.3 (q,
J = 273.9 Hz, C0), 118.7 (CH2), 71.5 (CH), 41.8 (CH2); HRMS (ESI+)
m/z: Calcd for C13H12F3 [M+H+18] 225.0891, found 225.0911.
4.1.7.2. (E)-1-(4-(Triﬂuoromethyl)phenyl)hexa-1,5-dien-3-ol
(70). Prepared according to the general procedure for the ally-
lation reactions in 99% yield (yellow oil). Eluent: hexanes/ethyl
acetate 4:1 v/v. IR (cm1, thin ﬁlm): 3411, 3079, 2981, 2933,
1642, 1616, 1579, 1514, 1415, 1326, 1166, 1125, 1067, 1017,
971, 921, 863, 838, 819; 1H NMR (250 MHz, CDCl3,): d 7.54 (d,
J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 6.63 (d, J = 15.9 Hz, 1H),
6.33 (dd, J = 15.9 and 5.9 Hz, 1H), 5.95–5.75 (m, 1H), 5.25–5.11
(m, 2H), 4.38 (q, J = 5.9 Hz, 1H), 2.52–2.31 (m, 3H); 13C NMR
(62.5 MHz, CDCl3): d 140.2 (C0), 134.3 (CH), 133.7 (CH), 129.3 (q,
J = 32.3 Hz, C0), 128.7 (CH), 126.6 (2  CH), 125.5 (q, J = 3.9 Hz,
2  CH), 124.2 (q, J = 271.3 Hz, C0), 118.6 (CH2), 71.3 (CH), 41.9
(CH2); HRMS (ESI+) m/z: Calcd for C13H12F3 [M+H+18] 225.0891,
found 225.0962.
4.1.7.3. (E)-1-(4-Methoxyphenyl)hexa-1,5-dien-3-ol (71).
Prepared according to the general procedure for the allylation reac-
tions in quantitative yield (yellow oil). Eluent: hexanes/ethyl ace-
tate 3:2 v/v. IR (cm1, thin ﬁlm): 3409, 3075, 3004, 2934, 2904,
2837, 1641, 1607, 1578, 1512, 1465, 1302, 1250, 1175, 1033,
969, 917, 816; 1H NMR (250 MHz, CDCl3): d 7.26 (d, J = 8.7 Hz,
2H), 6.81 (d, J = 8.7 Hz, 2H), 6.50 (d, J = 15.9 Hz, 1H), 6.09 (dd,
J = 15.9 and 6.6 Hz, 1H), 5.87 (dtd, J = 17.2, 10.2, 6.6 and 6.6 Hz,
1H), 5.20–5.07 (m, 2H), 4.29 (q, J = 6.6 Hz, 1H), 3.72 (s, 3H), 3.26
(br s, 1H), 2.39 (t, J = 6.6 Hz, 2H); 13C NMR (62.5 MHz, CDCl3): d
158.7 (C0), 134.1 (CH), 129.3 (2  CH), 129.1 (C0), 127.2 (2  CH),
117.2 (CH2), 113.5 (2  CH), 71.6 (CH), 54.7 (OCH3), 41.6 (CH2);HRMS (ESI+) m/z: Calcd for C13H15O [M+H+18] 187.1123, found
187.1203.
4.1.7.4. (E)-1-(2,4-Dimethoxyphenyl)hexa-1,5-dien-3-ol (72).
Prepared according to the general procedure for the allylation reac-
tions in quantitative yield (yellow oil). Eluent: hexanes/ethyl ace-
tate 2:1 v/v. IR (cm1, thin ﬁlm): 3442, 3072, 3002, 2938, 2838,
1638, 1609, 1505, 1465, 1209, 1159, 1034, 921, 834; 1H NMR
(250 MHz, CDCl3): d 7.33 (d, J = 8.2 Hz, 1H), 6.81 (d, J = 16.0 Hz,
1H), 6.47 (d, J = 2.3 Hz, 1H), 6.45–6.41 (m, 1H), 6.13 (dd, J = 16.0
and 6.8 Hz, 1H), 5.87 (dtd, J = 17.2, 10.2, 6.8 and 6.8 Hz, 1H),
5.21–5.08 (m, 2H), 4.32 (q, J = 6.8 Hz, 1H), 3.80 (s, 3H), 3.79 (s,
3H), 2.40 (app t, J = 6.8 Hz, 2H), 2.06 (br s, 1H); 13C NMR
(62.5 MHz, CDCl3): d 160.4 (C0), 157.8 (C0), 134.4 (CH), 130.1
(CH), 127.5 (CH), 125.0 (CH), 118.6 (C0), 117.8 (CH2), 104.7 (CH),
98.3 (CH), 72.4 (CH), 55.3 (OCH3), 55.2 (OCH3), 42.0 (CH2); HRMS
(ESI+) m/z: Calcd for C14H17O2 [M+H+18] 217.1228, found
217.1205.
4.1.7.5. (E)-1-(3,4-Dimethoxyphenyl)hexa-1,5-dien-3-ol (73).
Prepared according to the general procedure for the allylation reac-
tions in 94% yield (yellow oil). Eluent: hexanes/ethyl acetate 1:1 v/
v. IR (cm1, thin ﬁlm): 3479, 3075, 3002, 2936, 2909, 2837, 1678,
1641, 1600, 1586, 1515, 1464, 1265, 1139, 1026, 969, 918, 863;
1H NMR (250 MHz, CDCl3): d 6.95–6.87 (m, 2H), 6.79 (app d,
J = 8.0 Hz, 1H), 6.52 (d, J = 15.9 Hz, 1H), 6.09 (dd, J = 15.9 and
6.5 Hz, 1H), 5.85 (dtd, J = 17.2, 10.2, 6.5 and 6.5 Hz, 1H), 5.22–
5.10 (m, 2H), 4.32 (q, J = 6.5 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 3H),
2.44–2.34 (m, 2H), 1.92 (br s, 1H); 13C NMR (62.5 MHz, CDCl3): d
149.0 (C0), 148.8 (C0), 134.1 (CH), 130.1 (CH), 129.7 (C0), 129.6
(CH), 119.6 (CH), 118.2 (CH2), 111.1 (CH), 108.9 (CH), 71.8 (CH),
55.8 (2  OCH3), 42.0 (CH2); HRMS (ESI+) m/z: Calcd for C14H17O2
[M+H+18] 217.1228, found 217.1205.
4.1.7.6. (E)-1-(3,5-Dimethoxyphenyl)hexa-1,5-dien-3-ol (74).
Prepared according to the general procedure for the allylation reac-
tions in quantitative yield (light brown viscous oil). Eluent: hex-
anes/ethyl acetate 1:1 v/v. IR (cm1, thin ﬁlm): 3418, 3076, 3002,
2937, 2838, 1640, 1593, 1459, 1427, 1205, 1154, 1064, 969, 923,
828; 1H NMR (250 MHz, CDCl3): d 6.52 (d, J = 2.1 Hz, 2H), 6.49 (d,
J = 15.9 Hz, 1H), 6.36 (t, J = 2.1 Hz, 1H), 6.20 (dd, J = 15.9 and
6.3 Hz, 1H), 5.84 (dtd, J = 17.2, 10.2, 6.3 and 6.3 Hz, 1H), 5.20–
5.07 (m, 2H), 4.30 (q, J = 6.3 Hz, 1H), 3.75 (s, 6H), 2.45 (br s, 1H),
2.38 (app t, J = 6.3 Hz, 2H); 13C NMR (62.5 MHz, CDCl3): d 160.7
(2  C0), 138.6 (C0), 134.0 (CH), 132.1 (CH), 129.9 (CH), 118.0
(CH2), 104.4 (2  CH), 99.7 (CH), 71.4 (CH), 55.1 (2  OCH3), 41.7
(CH2); HRMS (ESI+) m/z: Calcd for C14H19O3 [M+H+] 235.1334,
found 235.1407.
4.1.7.7. (E)-1-(3,4,5-Trimethoxyphenyl)hexa-1,5-dien-3-ol (75).
Prepared according to the general procedure for the allylation reac-
tions in 92% yield (yellow oil). Eluent: hexanes/ethyl acetate 3:2 v/
v. IR (cm1, thin ﬁlm): 3439, 3074, 2999, 2938, 2838, 1640, 1584,
1507, 1463, 1420, 1329, 1241, 1127, 1004, 969, 919, 814; 1H
NMR (250 MHz, CDCl3): d 6.55 (s, 2H), 6.47 (d, J = 15.9 Hz, 1H),
6.11 (dd, J = 15.9 and 6.5 Hz, 1H), 5.82 (dtd, J = 17.2, 10.2, 6.5 and
6.5 Hz, 1H), 5.18–5.06 (m, 2H), 4.30 (q, J = 6.5 Hz, 1H), 3.82 (s,
6H), 3.80 (s, 3H), 2.42–2.32 (m, 2H), 2.23 (br s, 1H); 13C NMR
(62.5 MHz, CDCl3): d 153.1 (2  C0), 137.7 (C0), 134.0 (CH), 132.3
(C0), 131.0 (CH), 130.0 (CH), 118.1 (CH2), 103.5 (2  CH), 71.5
(CH), 60.7 (OCH3), 55.9 (2  OCH3), 41.8 (CH2); HRMS (ESI+) m/z:
Calcd for C15H21O4 [M+H+] 265.1440, found 265.1553.
4.1.7.8. (E)-1-(2,4,5-Trimethoxyphenyl)hexa-1,5-dien-3-ol (76).
Prepared according to the general procedure for the allylation reac-
tions in 80% yield (yellow oil). Eluent: hexanes/ethyl acetate 1:1 v/
3646 R. C. Barcelos et al. / Bioorg. Med. Chem. 20 (2012) 3635–3651v. IR (cm1, thin ﬁlm): 3422, 3074, 3000, 2936, 2834, 1641, 1609,
1511, 1466, 1208, 1034, 973, 916, 874, 732; 1H NMR (250 MHz,
CDCl3): d 6.83 (s, 1H), 6.17 (d, J = 16.0 Hz, 1H), 6.34 (s, 1H), 5.99
(dd, J = 16.0 and 6.7 Hz, 1H), 5.86–5.64 (m, 1H), 5.12–4.91 (m,
2H), 4.26–4.11 (m, 1H), 3.73 (s, 3H), 3.70 (s, 3H), 3.65 (s, 3H),
2.67 (br s, 1H), 2.28 (t, J = 6.7 Hz, 2H); 13C NMR (62.5 MHz, CDCl3):
d 151.3 (C0), 149.4 (C0), 143.2 (C0), 134.3 (CH), 129.9 (CH), 124.7
(CH), 117.8 (CH2), 117.3 (C0), 109.9 (CH), 97.6 (CH), 72.3 (CH),
56.4 (2  OCH3), 55.9 (OCH3), 41.9 (CH2); HRMS (ESI+) m/z: Calcd
for C15H19O3 [M+H+18] 247.1334, found 247.1358.
4.1.8. General procedure for the esteriﬁcation reactions
To a solution of the homoallylic alcohols 69–76 (3.40 mmol) in
anhydrous CH2Cl2 (70 mL), at 0 C under magnetic stirring and
nitrogen atmosphere, was added triethylamine (2.0 equiv;
6.80 mmol), followed by acryloyl chloride (1.5 equiv; 5.10 mmol).
The cooling bath was removed and the reaction mixture was stir-
red for 1 h at room temperature. After this period, the volatiles
were removed under reduced pressure and the crude was puriﬁed
by ﬂash column chromatography (using the eluent indicated) to af-
ford the corresponding esters 77–84.
4.1.8.1. (E)-1-(2-(Triﬂuoromethyl)phenyl)hexa-1,5-dien-3-yl
acrylate (77). Prepared according to the general procedure
for the esteriﬁcation reactions in 61% yield (yellow oil). Eluent:
hexanes/ethyl acetate 9:1 v/v. IR (cm1, thin ﬁlm): 3078, 2928,
2855, 1726, 1638, 1576, 1406, 1315, 1189, 1165, 1124, 1036,
967, 809, 765; 1H NMR (250 MHz, CDCl3): d 7.65–7.55 (m, 2H),
7.48 (t, J = 7.6 Hz, 1H), 7.38–7.29 (m, 1H), 7.02 (d, J = 16.0 Hz,
1H), 6.46 (dd, J = 17.3 and 1.3 Hz, 1H), 6.23–6.10 (m, 2H), 5.91–
5.72 (m, 2H), 5.60 (q, J = 6.5 Hz, 1H), 5.22–5.07 (m, 2H), 2.55 (t,
J = 6.5 Hz, 2H); 13C NMR (62.5 MHz, CDCl3): d 165.2 (C0), 135.5
(q, J = 1.8 Hz, C0), 132.7 (CH), 131.8 (CH), 131.4 (CH), 130.9 (CH2),
128.5 (CH), 128.1 (q, J = 1.8 Hz, CH), 127.6 (q, J = 29.9 Hz, C0),
127.5 (2  CH), 125.7 (q, J = 5.8 Hz, CH), 124.2 (q, J = 274.0 Hz,
C0), 118.4 (CH2), 73.2 (CH), 38.9 (CH2); HRMS (ESI+) m/z: Calcd
for C16H16F3O2 [M+H+] 297.1102, found 297.1135.
4.1.8.2. (E)-1-(4-(Triﬂuoromethyl)phenyl)hexa-1,5-dien-3-yl
acrylate (78). Prepared according to the general procedure
for the esteriﬁcation reactions in 41% yield (yellow oil). Eluent:
hexanes/ethyl acetate 9:1 v/v. IR (cm1, thin ﬁlm): 3081, 2927,
2855, 1727, 1640, 1617, 1407, 1326, 1189, 1167, 1125, 1068,
970, 810; 1H NMR (250 MHz, CDCl3): d 7.56 (d, J = 8.4 Hz, 2H),
7.46 (d, J = 8.4 Hz, 2H), 6.66 (d, J = 16.0 Hz, 1H), 6.45 (dd, J = 17.3
and 1.5 Hz, 1H), 6.28 (dd, J = 16.0 and 7.0 Hz, 1H), 6.16 (dd,
J = 17.3 and 10.4 Hz, 1H), 5.86 (dd, J = 10.4 and 1.5 Hz, 1H), 5.81
(dtd, J = 17.4, 10.2, 7.0 and 7.0 Hz, 1H), 5.58 (q, J = 7.0 Hz, 1H),
5.19–5.08 (m, 2H), 2.55 (t, J = 7.0 Hz, 2H); 13C NMR (62.5 MHz,
CDCl3): d 165.3 (C0), 139.7 (C0), 132.7 (CH), 131.1 (CH), 131.0
(CH2), 129.7 (q, J = 32.3 Hz, C0), 129.7 (CH), 128.5 (CH), 126.7
(2  CH), 125.5 (q, J = 3.9 Hz, 2  CH), 124.3 (q, J = 272.2 Hz, C0),
118.4 (CH2), 73.5 (CH), 38.9 (CH2); HRMS (EI) m/z: Calcd for
C16H15F3O2 [M+] 296.1024, found 296.1039.
4.1.8.3. (E)-1-(4-methoxyphenyl)hexa-1,5-dien-3-yl acrylate
(79). Prepared according to the general procedure for the
esteriﬁcation reactions in 86% yield (yellow oil). Eluent: hexanes/
ethyl acetate 2:1 v/v. IR (cm1, thin ﬁlm): 3077, 3036, 3005,
2959, 2934, 2837, 1722, 1638, 1608, 1513, 1405, 1250, 1190,
1176, 1036, 966, 808; 1H NMR (250 MHz, CDCl3): d 7.27 (d,
J = 8.7 Hz, 2H), 6.80 (d, J = 8.7 Hz, 2H), 6.58 (d, J = 15.9 Hz, 1H),
6.40 (dd, J = 17.3 and 1.3 Hz, 1H), 6.12 (dd, J = 17.3 and 10.3 Hz,
1H), 6.03 (dd, J = 15.9 and 6.7 Hz, 1H), 5.88–5.69 (m, 1H), 5.75
(dd, J = 10.3 and 1.3 Hz, 1H), 5.54 (q, J = 6.7 Hz, 1H), 5.18–5.02
(m, 2H), 3.69 (s, 3H), 2.49 (t, J = 6.7 Hz, 2H); 13C NMR (62.5 MHz,CDCl3): d 164.8 (C0), 159.2 (C0), 132.8 (CH), 132.0 (CH), 130.1
(CH2), 128.5 (C0), 128.4 (CH), 127.4 (2  CH), 124.3 (CH), 117.6
(CH2), 113.6 (2  CH), 73.7 (CH), 54.6 (OCH3), 38.7 (CH2); HRMS
(ESI+) m/z: Calcd for C13H15O [M+H+72] 187.1123, found
187.1203.
4.1.8.4. (E)-1-(2,4-Dimethoxyphenyl)hexa-1,5-dien-3-yl acrylate
(80). Prepared according to the general procedure for the
esteriﬁcation reactions in 60% yield (yellow oil). Eluent: hexanes/
ethyl acetate 3:1 v/v. IR (cm1, thin ﬁlm): 3004, 2936, 2837,
1723, 1609, 1580, 1505, 1465, 1289, 1264, 1208, 1159, 1036,
974, 834; 1H NMR (250 MHz, CDCl3,): d 7.33 (d, J = 8.3 Hz, 1H),
6.88 (d, J = 16.0 Hz, 1H), 6.51–6.35 (m, 3H), 6.22–6.04 (m, 2H),
5.90–5.70 (m, 2H), 5.54 (q, J = 6.8 Hz, 1H), 5.18–5.04 (m, 2H),
3.82 (s, 3H), 3.81 (s, 3H), 2.52 (t, J = 6.8 Hz, 2H); 13C NMR
(62.5 MHz, CDCl3): d 165.5 (C0), 160.7 (C0), 158.1 (C0), 133.4 (CH),
130.4 (CH2), 128.9 (CH), 127.9 (CH), 127.7 (CH), 125.2 (CH), 118.3
(C0), 117.9 (CH2), 104.8 (CH), 98.4 (CH), 74.8 (CH), 55.4 (2  OCH3),
39.3 (CH2); HRMS (ESI+) m/z: Calcd for C14H17O2 [M+H+72]
217.1228, found 217.1308.
4.1.8.5. (E)-1-(3,4-Dimethoxyphenyl)hexa-1,5-dien-3-yl acrylate
(81). Prepared according to the general procedure for the
esteriﬁcation reactions in 60% yield (yellow oil). Eluent: hexanes/
ethyl acetate 2:1 v/v. IR (cm1, thin ﬁlm): 3077, 3002, 2956,
2937, 2837, 1722, 1639, 1602, 1586, 1515, 1465, 1406, 1266,
1192, 1027, 967, 809; 1H NMR (250 MHz, CDCl3): d 6.93–6.84 (m,
2H), 6.76 (d, J = 8.7 Hz, 1H), 6.55 (d, J = 15.9 Hz, 1H), 6.39 (d,
J = 17.3 Hz, 1H), 6.11 (dd, J = 17.3 and 10.3 Hz, 1H), 6.02 (dd,
J = 15.9 and 6.7 Hz, 1H), 5.87–5.67 (m, 1H), 5.78 (d, J = 10.3 Hz,
1H), 5.51 (q, J = 6.7 Hz, 1H), 5.17–5.01 (m, 2H), 3.85 (s, 3H), 3.82
(s, 3H), 2.50 (t, J = 6.7 Hz, 2H); 13C NMR (62.5 MHz, CDCl3): d
165.2 (C0), 149.0 (C0), 148.8 (C0), 132.9 (CH), 132.5 (CH), 130.5
(CH2), 129.1 (C0), 128.5 (CH), 124.7 (CH), 119.7 (CH), 117.9 (CH2),
110.9 (CH), 108.9 (CH), 73.9 (CH), 55.7 (OCH3), 55.6 (OCH3), 38.9
(CH2); HRMS (ESI+) m/z: Calcd for C17H21O4 [M+H+] 289.1440,
found 289.1489.
4.1.8.6. (E)-1-(3,5-Dimethoxyphenyl)hexa-1,5-dien-3-yl acrylate
(82). Prepared according to the general procedure for the
esteriﬁcation reactions in 92% yield (yellow oil). Eluent: hexanes/
ethyl acetate 2:1 v/v. IR (cm1, thin ﬁlm): 3078, 3002, 2939,
2838, 1723, 1636, 1593, 1457, 1428, 1405, 1295, 1268, 1205,
1193, 1154, 1066, 967, 809; 1H NMR (250 MHz, CDCl3): d 6.62–
6.35 (m, 5H), 6.24–6.06 (m, 2H), 5.90–5.70 (m, 2H), 5.55 (q,
J = 6.6 Hz, 1H), 5.19–5.06 (m, 2H), 3.77 (s, 6H), 2.52 (t, J = 6.6 Hz,
2H); 13C NMR (62.5 MHz, CDCl3): d 165.1 (C0), 160.8 (2  C0),
138.1 (C0), 132.8 (CH), 132.6 (CH), 130.6 (CH2), 128.5 (CH), 127.4
(CH), 118.1 (CH2), 104.5 (2  CH), 100.2 (CH), 73.6 (CH), 55.1
(2  OCH3), 38.9 (CH2); HRMS (ESI+) m/z: Calcd for C17H21O4
[M+H+] 289.1440, found 289.1381.
4.1.8.7. (E)-1-(3,4,5-Trimethoxyphenyl)hexa-1,5-dien-3-yl acry-
late (83). Prepared according to the general procedure for the
esteriﬁcation reactions in 82% yield (yellow oil). Eluent: hexanes/
ethyl acetate 2:1 v/v. IR (cm1, thin ﬁlm): 3077, 2998, 2940,
2840, 1722, 1638, 1619, 1583, 1507, 1463, 1455, 1420, 1405,
1330, 1241, 1190, 1127, 967, 810; 1H NMR (250 MHz, CDCl3): d
6.61–6.56 (m, 2H), 6.56 (d, J = 16.0 Hz, 1H), 6.43 (d, J = 17.3 Hz,
1H), 6.20–6.00 (m, 2H), 5.89–5.69 (m, 2H), 5.53 (q, J = 6.6 Hz,
1H), 5.19–5.09 (m, 2H), 3.85 (s, 6H), 3.82 (s, 3H), 2.52 (t,
J = 6.6 Hz, 2H); 13C NMR (62.5 MHz, CDCl3): d 165.3 (C0), 153.2
(2  C0), 138.1 (C0), 132.9 (CH), 132.8 (CH), 131.8 (C0), 130.7
(CH2), 128.6 (CH), 126.3 (CH), 118.1 (CH2), 103.7 (2  CH), 73.8
(CH), 60.8 (OCH3), 56.0 (2  OCH3), 39.0 (CH2); HRMS (ESI+) m/z:
Calcd for C15H19O3 [M+H+72] 247.1334, found 247.1389.
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late (84). Prepared according to the general procedure for the
esteriﬁcation reactions in 83% yield (yellow oil). Eluent: hexanes/
ethyl acetate 2:1 v/v. IR (cm1, thin ﬁlm): 2995, 2922, 2831,
1724, 1607, 1511, 1464, 1402, 1206, 1123, 1033, 985, 869; 1H
NMR (250 MHz, CDCl3): d 6.96–6.83 (m, 2H), 6.50–6.32 (m, 2H),
6.19–5.98 (m, 2H), 5.89–5.68 (m, 2H), 5.53 (q, J = 6.4 Hz, 1H),
5.17–5.00 (m, 2H), 3.85 (s, 3H), 3.82 (s, 3H), 3.78 (s, 3H), 2.51 (t,
J = 6.4 Hz, 2H); 13C NMR (62.5 MHz, CDCl3): d 165.3 (C0), 151.6
(C0), 149.7 (C0), 143.1 (C0), 133.2 (CH), 130.4 (CH2), 128.7 (CH),
127.3 (CH), 124.9 (CH), 117.8 (CH2), 116.8 (C0), 110.0 (CH), 97.5
(CH), 74.6 (CH), 56.4 (2  OCH3), 55.9 (OCH3), 39.1 (CH2); HRMS
(ESI+) m/z: Calcd for C15H19O3 [M+H+72] 247.1334, found
247.1389.
4.1.9. General Procedure for the Preparation of Lactones
To a solution of esters 77–84 (1.80 mmol) in CH2Cl2 (180 mL),
under reﬂux and magnetic stirring, was added Grubbs’ ﬁrst gener-
ation catalyst (10 mol %; 0.18 mmol). After 8.0 h under these con-
ditions, the reaction was allowed to cool to room temperature,
DMSO (50 equiv relative to the catalyst) was added and the mix-
ture was maintained under magnetic stirring overnight. After this
period, the solvent was removed under reduced pressure and the
residue was subjected to ﬂash column chromatography (using
the eluent indicated) to afford the corresponding lactones 85–92.
4.1.9.1. (E)-6-(2-(Triﬂuoromethyl)styryl)-5,6-dihydro-2H-pyran-
2-one (85). Prepared according to the general procedure for
the preparation of lactones in 70% yield (yellow oil). Eluent: hex-
anes/ethyl acetate 2:1 v/v. IR (cm1, thin ﬁlm): 3074, 2925, 1725,
1605, 1577, 1488, 1384, 1314, 1246, 1164, 1120, 1058, 1036,
968, 832, 815, 743; 1H NMR (500 MHz, CDCl3): d 7.66 (d,
J = 7.8 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.54 (t, J = 7.8 Hz, 1H), 7.40
(t, J = 7.8 Hz, 1H), 7.08 (d, J = 15.9 Hz, 1H), 6.94 (ddd, J = 9.7, 4.8
and 3.8 Hz, 1H), 6.28 (dd, J = 15.9 and 6.5 Hz, 1H), 6.11 (dt, J = 9.7
and 1.7 Hz, 1H), 5.17–5.12 (m, 1H), 2.60–2.56 (m, 2H); 13C NMR
(62.5 MHz, CDCl3): d 163.6 (C0), 144.5 (CH), 134.9 (q, J = 1.5 Hz,
C0), 132.0 (CH), 130.2 (CH), 129.2 (q, J = 1.6 Hz, CH), 128.0 (CH),
127.7 (q, J = 30.0 Hz, C0), 127.6 (CH), 125.8 (q, J = 5.7 Hz, CH),
124.1 (q, J = 273.7 Hz, C0), 121.6 (CH), 77.7 (CH), 29.6 (CH2); HRMS
(ESI+)m/z: Calcd for C14H12F3O2 [M+H+] 269.0789, found 269.0835.
4.1.9.2. (E)-6-(4-(Triﬂuoromethyl)styryl)-5,6-dihydro-2H-pyran-
2-one (86). Prepared according to the general procedure for
the preparation of lactones in 73% yield (yellow solid). Eluent: hex-
anes/ethyl acetate 2:1 v/v. Mp: 72.3–74.2 C; IR (cm1, thin
ﬁlm): 2922, 1714, 1615, 1428, 1418, 1384, 1328, 1245, 1162,
1120, 1069, 1017, 971, 861, 814; 1H NMR (500 MHz, CDCl3): d
7.59 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.3 Hz, 2H), 6.93 (ddd, J = 9.7,
5.3 and 3.2 Hz, 1H), 6.78 (d, J = 16.0 Hz, 1H), 6.36 (dd, J = 16.0 and
5.9 Hz, 1H), 6.11 (ddd, J = 9.7, 2.3 and 1.3 Hz, 1H), 5.16–5.11 (m,
1H), 2.63–2.50 (m, 2H); 13C NMR (62.5 MHz, CDCl3): d 163.6 (C0),
144.7 (CH), 139.3 (C0), 131.4 (CH), 130.0 (q, J = 32.3 Hz, C0), 128.3
(CH), 126.9 (2  CH), 125.6 (q, J = 3.8 Hz, 2  CH), 124.0 (q,
J = 271.9 Hz, C0), 121.5 (CH), 77.4 (CH), 29.7 (CH2); HRMS (ESI+)
m/z: Calcd for C14H12F3O2 [M+H+] 269.0789, found 269.0730.
4.1.9.3. (E)-6-(4-Methoxystyryl)-5,6-dihydro-2H-pyran-2-one
(87). Prepared according to the general procedure for the
preparation of lactones in 74% yield (white solid). Eluent: hex-
anes/ethyl acetate 1:1 v/v. Mp: 110.6–112.5 C; IR (cm1, thin
ﬁlm): 3045, 2936, 2839, 1712, 1651, 1605, 1513, 1455, 1420,
1245, 1145, 1025, 968, 849, 809, 771; 1H NMR (500 MHz, CDCl3):
d 7.32 (d, J = 8.7 Hz, 2H), 6.90 (dt, J = 9.7 and 4.3 Hz, 1H), 6.85 (d,
J = 8.7 Hz, 2H), 6.64 (d, J = 15.9 Hz, 1H), 6.12 (dd, J = 15.9 and
6.6 Hz, 1H), 6.06 (dt, J = 9.7 and 1.8 Hz, 1H), 5.08–5.02 (m, 1H),3.79 (s, 3H), 2.53–2.49 (m, 2H); 13C NMR (62.5 MHz, CDCl3): d
163.9 (C0), 159.6 (C0), 144.7 (CH), 132.6 (CH), 128.3 (C0), 127.8
(2  CH), 123.3 (CH), 121.3 (CH), 113.9 (2  CH), 78.1 (CH), 55.1
(OCH3), 29.8 (CH2); HRMS (ESI+) m/z: Calcd for C14H15O3 [M+H+]
231.1021, found 231.1013.
4.1.9.4. (E)-6-(2,4-Dimethoxystyryl)-5,6-dihydro-2H-pyran-2-
one (88). Prepared according to the general procedure for
the preparation of lactones in 50% yield (yellow solid). Eluent: hex-
anes/ethyl acetate 1:1 v/v. Mp: 72.4–74.6 C; IR (cm1, thin ﬁlm):
3003, 2940, 2838, 1719, 1608, 1505, 1465, 1384, 1247, 1209,
1160, 1031, 972, 815, 734; 1H NMR (500 MHz, CDCl3): d 7.33 (d,
J = 8.5 Hz, 1H), 6.91 (d, J = 16.0 Hz, 1H), 6.90 (dt, J = 9.8 and
4.5 Hz, 1H), 6.47 (dd, J = 8.5 and 2.4 Hz, 1H), 6.43 (d, J = 2.4 Hz,
1H), 6.21 (dd, J = 16.0 and 6.9 Hz, 1H), 6.06 (dt, J = 9.8 and 1.8 Hz,
1H), 5.08–5.02 (m, 1H), 3.82 (s, 3H), 3.81 (s, 3H), 2.55–2.50 (m,
2H); 13C NMR (62.5 MHz, CDCl3): d 164.0 (C0), 160.7 (C0), 157.9
(C0), 144.9 (CH), 128.0 (CH), 127.8 (CH), 123.7 (CH), 121.0 (CH),
117.4 (C0), 104.7 (CH), 98.0 (CH), 78.8 (CH), 55.1 (2  OCH3), 29.7
(CH2); HRMS (ESI+) m/z: Calcd for C15H17O4 [M+H+] 261.1127,
found 261.1112.
4.1.9.5. (E)-6-(3,4-Dimethoxystyryl)-5,6-dihydro-2H-pyran-2-
one (89). Prepared according to the general procedure for
the preparation of lactones in 45% yield (yellow solid). Eluent: hex-
anes/ethyl acetate 1:1 v/v. Mp: 116.0–118.0 C; IR (cm1, thin
ﬁlm): 3001, 2934, 2843, 1715, 1602, 1585, 1515, 1464, 1421,
1383, 1266, 1251, 1141, 1023, 968, 817; 1H NMR (500 MHz,
CDCl3): d 6.95–6.89 (m, 3H), 6.82 (d, J = 8.5 Hz, 1H), 6.64 (d,
J = 15.9 Hz, 1H), 6.13 (dd, J = 15.9 and 6.5 Hz, 1H), 6.07 (dt, J = 9.8
and 1.6 Hz, 1H), 5.10–5.04 (m, 1H), 3.89 (s, 3H), 3.87 (s, 3H),
2.57–2.50 (m, 2H); 13C NMR (62.5 MHz, CDCl3): d 163.7 (C0),
149.1 (C0), 148.8 (C0), 144.7 (CH), 132.7 (CH), 128.5 (C0), 123.4
(CH), 121.2 (CH), 119.9 (CH), 110.9 (CH), 108.7 (CH), 77.9 (CH),
55.6 (2  OCH3), 29.6 (CH2); HRMS (ESI+) m/z: Calcd for C15H17O4
[M+H+] 261.1127, found 261.1207.
4.1.9.6. (E)-6-(3,5-Dimethoxystyryl)-5,6-dihydro-2H-pyran-2-
one (90). Prepared according to the general procedure for
the preparation of lactones in 88% yield (yellow oil). Eluent: hex-
anes/ethyl acetate 1:1 v/v. IR (cm1, thin ﬁlm): 3002, 2940, 2840,
1721, 1661, 1592, 1459, 1428, 1383, 1246, 1205, 1154, 1060,
967, 818, 734; 1H NMR (500 MHz, CDCl3): d 6.91 (ddd, J = 9.7, 5.0
and 3.5 Hz, 1H), 6.64 (d, J = 15.8 Hz, 1H), 6.53 (d, J = 2.2 Hz, 2H),
6.39 (t, J = 2.2 Hz, 1H), 6.24 (dd, J = 15.9 and 6.3 Hz, 1H), 6.07 (dt,
J = 9.7 and 1.4 Hz, 1H), 5.11–5.05 (m, 1H), 3.79 (s, 6H), 2.58–2.47
(m, 2H); 13C NMR (62.5 MHz, CDCl3): d 163.4 (C0), 160.5 (2  C0),
144.8 (CH), 137.4 (C0), 132.4 (CH), 125.9 (CH), 120.8 (CH), 104.3
(2  CH), 100.0 (CH), 77.4 (CH), 54.8 (2  OCH3), 29.3 (CH2); HRMS
(ESI+) m/z: Calcd for C15H17O4 [M+H+] 261.1127, found 261.1112.
4.1.9.7. (E)-6-(3,4,5-Trimethoxystyryl)-5,6-dihydro-2H-pyran-2-
one (91). Prepared according to the general procedure for the
preparation of lactones in 70% yield (yellow solid). Eluent: hex-
anes/ethyl acetate 1:2 v/v. Mp: 117.6–119.0 C; IR (cm1, thin
ﬁlm): 2940, 2840, 1721, 1658, 1583, 1508, 1463, 1455, 1421,
1244, 1125, 1018, 967, 817; 1H NMR (500 MHz, CDCl3): d 6.91
(ddd, J = 13.3, 4.9 and 3.5 Hz, 1H), 6.62 (d, J = 15.9 Hz, 1H), 6.64–
6.62 (m, 2H), 6.17 (dd, J = 15.9 and 6.3 Hz, 1H), 6.06 (dt, J = 9.8
and 1.5 Hz, 1H), 5.14–5.06 (m, 1H), 3.85 (s, 6H), 3.82 (s, 3H),
2.62–2.50 (m, 2H); 13C NMR (62.5 MHz, CDCl3): d 163.3 (C0),
152.8 (2  C0), 144.7 (CH), 137.8 (C0), 132.4 (CH), 131.0 (C0),
124.8 (CH), 120.7 (CH), 103.3 (2  CH), 77.4 (CH), 60.3 (OCH3),
55.5 (2  OCH3), 29.2 (CH2); HRMS (ESI+) m/z: Calcd for C16H19O5
[M+H+] 291.1233, found 291.1263.
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one (92). Prepared according to the general procedure for the
preparation of lactones in 45% yield (yellow solid). Eluent: hex-
anes/ethyl acetate 1:1 v/v. Mp: 101.4–102.8 C; IR (cm1, thin
ﬁlm): 2995, 2934, 2825, 1714, 1586, 1513, 1464, 1404, 1208,
1030, 873, 816; 1H NMR (250 MHz, CDCl3): d 7.00–6.86 (m, 3H),
6.49 (s, 1H), 6.18 (dd, J = 16.1 and 6.9 Hz, 1H), 6.07 (dt, J = 9.7
and 1.7 Hz, 1H), 5.13–5.02 (m, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.82
(s, 3H), 2.58–2.50 (m, 2H); 13C NMR (62.5 MHz, CDCl3): d 163.9
(C0), 151.7 (C0), 150.0 (C0), 144.8 (CH), 143.1 (C0), 127.8 (CH),
123.7 (CH), 121.3 (CH), 116.1 (C0), 109.9 (CH), 97.2 (CH), 78.7
(CH), 56.3 (2  OCH3), 55.9 (OCH3), 29.8 (CH2) ; HRMS (ESI+) m/z:
Calcd for C16H19O5 [M+H+] 291.1233, found 291.1232.
4.1.10. General Procedure for the Preparation of the Amides
To a stirred solution of lithium hexamethyldisilazide (1.2 equiv;
5.93 mmol) in anhydrous THF (20 mL), at 0 C under nitrogen
atmosphere, was added a solution of the homologated aldehyde
61–68, 93 (4,94 mmol) in anhydrous THF (5 mL). After 15 min un-
der these conditions, a solution of allylmagnesium bromide in
diethyl ether (1.2 equiv; 5.93 mmol) was added dropwise and the
resulting solution was stirred at room temperature for 30 min.
After this period, a saturated aqueous solution of ammonium chlo-
ride (35 mL) was added and the layers were separated. The aque-
ous layer was extracted with CH2Cl2 (3  15 mL) and the
combined organic layers were dried over anhydrous MgSO4, ﬁl-
tered and concentrated under reduced pressure. The crude was dis-
solved in anhydrous CH2Cl2 (50 mL), triethylamine (2.0 equiv;
9.88 mmol) was added and the resulting solution was cooled to
0 C. Acryloyl chloride (1.5 equiv; 7.41 mmol) was then added
dropwise and the reaction mixture was stirred for 1 h at room tem-
perature. After completion (indicated by TLC analysis), the volatiles
were removed under reduced pressure and the crude was puriﬁed
by ﬂash column chromatography (using the eluent indicated), giv-
ing the corresponding amides 94–102.
4.1.10.1. (E)-N-(1-Phenylhexa-1,5-dien-3-yl)acrylamide (94).
Prepared according to the general procedure for the preparation
of the amides in 85% yield (white solid). Eluent: hexanes/ethyl ace-
tate 1:2 v/v. Mp: 94.2–96.0 C; IR (cm1, thin ﬁlm): 3277, 3079,
3028, 2979, 2927, 1657, 1627, 1553, 1406, 1250, 1070, 992, 967,
926, 745; 1H NMR (250 MHz, CDCl3): d 7.38–7.18 (m, 5H), 6.53
(d, J = 16.1 Hz, 1H), 6.31 (dd, J = 17.0 and 1.6 Hz, 1H), 6.22–6.08
(m, 2H), 5.93 (br s, 1H), 5.81 (dtd, J = 17.0, 10.0, 7.0 and 7.0 Hz,
1H), 5.65 (dd, J = 10.0 and 1.6 Hz, 1H), 5.20–5.08 (m, 2H), 4.90–
4.76 (m, 1H), 2.45 (t, J = 7.0 Hz, 2H); 13C NMR (62.5 MHz, CDCl3):
d 164.8 (C0), 136.5 (C0), 133.7 (CH), 130.9 (CH), 130.7 (CH), 128.9
(CH), 128.5 (2  CH), 127.6 (CH), 126.6 (CH2), 126.4 (2  CH),
118.4 (CH2), 50.1 (CH), 39.3 (CH2); HRMS (ESI+) m/z: Calcd for
C15H18NO [M+H+] 228.1388, found 228.1422.4.1.10.2. (E)-N-(1-(2-(Triﬂuoromethyl)phenyl)hexa-1,5-dien-3-
yl)acrylamide (95). Prepared according to the general proce-
dure for the preparation of the amides in 60% yield (yellow oil).
Eluent: hexanes/ethyl acetate 2:1 v/v. IR (cm1, thin ﬁlm): 3271,
3075, 2982, 2933, 1658, 1628, 1544, 1488, 1409, 1315, 1164,
1124, 1060, 1036, 966, 921, 765; 1H NMR (250 MHz, CDCl3): d
7.61 (d, J = 7.8 Hz, 1H), 7.56 (d, J = 7.8 Hz, 1H), 7.51–7.42 (m, 1H),
7.38–7.28 (m, 1H), 6.88 (d, J = 15.8 Hz, 1H), 6.31 (dd, J = 17.0 and
1.6 Hz, 1H), 6.22–6.07 (m, 2H), 5.90–5.70 (m, 2H), 5.67 (dd,
J = 10.0 and 1.6 Hz, 1H), 5.22–5.10 (m, 2H), 4.92–4.78 (m, 1H),
2.45 (t, J = 6.4 Hz, 2H); 13C NMR (62.5 MHz, CDCl3): d 164.9 (C0),
135.8 (C0), 133.5 (CH), 133.4 (CH), 131.8 (CH), 130.7 (CH), 127.6
(CH), 127.4 (q, J = 29.9 Hz, C0), 127.3 (CH), 126.7 (CH2), 126.5 (q,
J = 1.6 Hz, CH), 125.7 (q, J = 5.7 Hz, CH), 124.3 (q, J = 273.4 Hz, C0),118.7 (CH2), 49.9 (CH), 39.0 (CH2); HRMS (ESI+) m/z: Calcd for
C16H17F3NO [M+H+] 296.1262, found 296.1331.
4.1.10.3. (E)-N-(1-(4-(Triﬂuoromethyl)phenyl)hexa-1,5-dien-3-
yl)acrylamide (96). Prepared according to the general proce-
dure for the preparation of the amides in 50% yield (white solid).
Eluent: hexanes/ethyl acetate 2:1 v/v. Mp: 113.6–115.3 C; IR
(cm1, thin ﬁlm): 3280, 3069, 2981, 2934, 1660, 1631, 1548,
1409, 1330, 1245, 1164, 1122, 1069, 958, 925, 811; 1H NMR
(250 MHz, CDCl3): d 7.54 (d, J = 8.3 Hz, 2H), 7.42 (d, J = 8.3 Hz,
2H), 6.55 (d, J = 16.1 Hz, 1H), 6.32 (dd, J = 17.0 and 1.6 Hz, 1H),
6.25 (dd, J = 16.1 and 6.5 Hz, 1H), 6.15 (dd, J = 17.0 and 10.0 Hz,
1H), 5.90–5.70 (m, 2H), 5.67 (dd, J = 10.0 and 1.6 Hz, 1H), 5.21–
5.10 (m, 2H), 4.84 (quint, J = 6.5 Hz, 1H), 2.46 (t, J = 6.5 Hz, 2H);
13C NMR (62.5 MHz, CDCl3): d 165.2 (C0), 140.1 (C0), 133.5 (CH),
131.9 (CH), 130.9 (CH), 129.3 (q, J = 32.7 Hz, C0), 129.2 (CH),
126.7 (CH2), 126.5 (2  CH), 125.4 (q, J = 3.8 Hz, 2  CH), 124.1
(q, J = 271.6 Hz, C0), 118.5 (CH2), 50.3 (CH), 39.2 (CH2); HRMS
(ESI+) m/z: Calcd for C16H17F3NO [M+H+] 296.1262, found
296.1364.
4.1.10.4. (E)-N-(1-(4-Methoxyphenyl)hexa-1,5-dien-3-yl)acryl-
amide (97). Prepared according to the general procedure for
the preparation of the amides in 84% yield (white solid). Eluent:
hexanes/ethyl acetate 2:1 v/v. Mp: 128.0–130.0 C; IR (cm1, thin
ﬁlm): 3276, 3075, 3005, 2979, 2954, 2932, 2905, 2834, 1658,
1627, 1606, 1545, 1512, 1248, 1178, 1033, 971, 915, 803; 1H
NMR (250 MHz, CDCl3): d 7.25 (d, J = 8.6 Hz, 2H), 6.81 (d,
J = 8.6 Hz, 2H), 6.46 (d, J = 15.9 Hz, 1H), 6.29 (dd, J = 16.9 and
1.9 Hz, 1H), 6.22–6.08 (m, 2H), 6.00 (dd, J = 15.9 and 6.2 Hz, 1H),
5.79 (dtd, J = 17.2, 10.2, 6.2 and 6.2 Hz, 1H), 5.61 (dd, J = 9.8 and
1.9 Hz, 1H), 5.18–5.04 (m, 2H), 4.78 (quint, J = 6.2 Hz, 1H), 3.77
(s, 3H), 2.42 (t, J = 6.2 Hz, 2H); 13C NMR (62.5 MHz, CDCl3): d
164.8 (C0), 159.1 (C0), 133.8 (CH), 130.9 (CH), 130.1 (CH), 129.3
(C0), 127.5 (2  CH), 126.7 (CH), 126.4 (CH2), 118.1 (CH2), 113.8
(2  CH), 55.2 (OCH3), 50.2 (CH), 39.4 (CH2); HRMS (ESI+) m/z:
Calcd for C16H20NO2 [M+H+] 258.1494, found 258.1542.
4.1.10.5. (E)-N-(1-(2,4-Dimethoxyphenyl)hexa-1,5-dien-3-yl)-
acrylamide (98). Prepared according to the general procedure
for the preparation of the amides in 50% yield (yellow solid). Elu-
ent: hexanes/ethyl acetate 2:1 v/v. Mp: 79.1–81.0 C; IR (cm1,
thin ﬁlm): 3276, 3074, 3002, 2938, 2837, 1658, 1609, 1504, 1465,
1439, 1209, 1159, 1035, 972, 835; 1H NMR (250 MHz, CDCl3, d):
7.25 (d, J = 8.4 Hz, 1H), 6.74 (d, J = 16.0 Hz, 1H), 6.45 (d, J = 8.4 Hz,
1H), 6.42–6.35 (m, 2H), 6.27 (dd, J = 17.0 and 2.6 Hz, 1H), 6.16
(dd, J = 17.0 and 9.2 Hz, 1H), 6.04 (dd, J = 16.0 and 7.0 Hz, 1H),
5.78 (dtd, J = 17.2, 10.2, 7.0 and 7.0 Hz, 1H), 5.55 (dd, J = 9.2 and
2.6 Hz, 1H), 5.13–5.00 (m, 2H), 4.83–4.68 (m, 1H), 3.74 (s, 3H),
3.73 (s, 3H), 2.40 (t, J = 7.0 Hz, 2H); 13C NMR (62.5 MHz, CDCl3): d
164.7 (C0), 160.2 (C0), 157.6 (C0), 134.0 (CH), 131.0 (CH), 127.4
(CH), 127.1 (CH), 126.0 (CH2), 125.1 (CH), 118.5 (C0), 117.7 (CH2),
104.6 (CH), 98.1 (CH), 55.2 (OCH3), 55.1 (OCH3), 50.7 (CH), 39.4
(CH2); HRMS (ESI+) m/z: Calcd for C17H22NO3 [M+H+] 288.1600,
found 288.1629.
4.1.10.6. (E)-N-(1-(3,4-Dimethoxyphenyl)hexa-1,5-dien-3-
yl)acrylamide (99). Prepared according to the general proce-
dure for the preparation of the amides in 60% yield (yellow oil).
Eluent: hexanes/ethyl acetate 2:1 v/v. IR (cm1, thin ﬁlm): 3280,
3074, 3002, 2936, 2911, 2836, 1659, 1627, 1603, 1515, 1464,
1264, 1238, 1139, 1026, 965, 803; 1H NMR (250 MHz, CDCl3): d
7.14 (d, J = 8.5 Hz, 1H), 6.75–6.58 (m, 3H), 6.33 (d, J = 16.0 Hz,
1H), 6.22–6.16 (m, 2H), 5.90 (dd, J = 16.0 and 6.4 Hz, 1H), 5.77–
5.57 (m, 1H), 5.51–5.41 (m, 1H), 5.05–4.88 (m, 2H), 4.73–4.58
(m, 1H), 3.68 (s, 6H), 2.40 (t, J = 6.4 Hz, 2H); 13C NMR (62.5 MHz,
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130.0 (CH), 129.4 (C0), 126.8 (CH), 126.0 (CH2), 119.1 (CH), 117.5
(CH2), 110.8 (CH), 108.6 (CH), 55.4 (OCH3), 55.3 (OCH3), 50.2
(CH), 39.0 (CH2); HRMS (ESI+) m/z: Calcd for C17H22NO3 [M+H+]
288.1600, found 288.1629.
4.1.10.7. (E)-N-(1-(3,5-Dimethoxyphenyl)hexa-1,5-dien-3-
yl)acrylamide (100). Prepared according to the general pro-
cedure for the preparation of the amides in 50% yield (yellow
oil). Eluent: hexanes/ethyl acetate 2:1 v/v. IR (cm1, thin ﬁlm):
3283, 3075, 3002, 2938, 2838, 1659, 1627, 1593, 1538, 1461,
1427, 1205, 1154, 1064, 967, 923, 828; 1H NMR (250 MHz, CDCl3):
d 6.67 (d, J = 8.5 Hz, 1H), 6.44 (d, J = 2.2 Hz, 2H), 6.39–6.18 (m, 4H),
6.10 (dd, J = 15.9 and 6.5 Hz, 1H), 5.75 (dtd, J = 17.1, 10.3, 6.5 and
6.5 Hz, 1H), 5.57 (dd, J = 8.9 and 2.9 Hz, 1H), 5.13–5.00 (m, 2H),
4.75 (quint, J = 6.5 Hz, 1H), 3.71 (s, 6H), 2.37 (t, J = 6.5 Hz, 2H);
13C NMR (62.5 MHz, CDCl3): d 164.8 (C0), 160.6 (2  C0), 138.5
(C0), 133.7 (CH), 130.8 (CH), 130.3 (CH), 129.4 (CH), 126.2 (CH2),
117.9 (CH2), 104.3 (2  CH), 99.6 (CH), 55.0 (2  OCH3), 50.1
(CH), 39.0 (CH2); HRMS (ESI+) m/z: Calcd for C17H22NO3 [M+H+]
288.1600, found 288.1629.
4.1.10.8. (E)-N-(1-(3,4,5-Trimethoxyphenyl)hexa-1,5-dien-3-
yl)acrylamide (101). Prepared according to the general pro-
cedure for the preparation of the amides in 75% yield (yellow so-
lid). Eluent: hexanes/ethyl acetate 2:1 v/v. Mp: 104.2–106.0 C;
IR (cm1, thin ﬁlm): 3284, 2938, 2839, 1658, 1627, 1583, 1508,
1420, 1240, 1127, 1004, 964, 920, 807; 1H NMR (250 MHz, CDCl3):
d 6.58–6.45 (m, 3H), 6.37 (d, J = 15.8 Hz, 1H), 6.30–6.09 (m, 2H),
6.00 (dd, J = 15.8 and 6.5 Hz, 1H), 5.73 (dtd, J = 17.2, 10.2, 6.5 and
6.5 Hz, 1H), 5.55 (dd, J = 9.0 and 2.8 Hz, 1H), 5.12–4.98 (m, 2H),
4.72 (quint, J = 6.5 Hz, 1H), 3.76 (s, 9H), 2.37 (t, J = 6.5 Hz, 2H);
13C NMR (62.5 MHz, CDCl3): d 164.7 (C0), 152.8 (2  C0), 137.3
(C0), 133.7 (CH), 132.2 (C0), 130.8 (CH), 130.2 (CH), 128.4 (CH),
126.0 (CH2), 117.6 (CH2), 103.1 (2  CH), 60.4 (OCH3), 55.6
(2  OCH3), 50.1 (CH), 38.9 (CH2); HRMS (ESI+) m/z: Calcd for
C18H24NO4 [M+H+] 318.1705, found 318.1799.
4.1.10.9. (E)-N-(1-(2,4,5-Trimethoxyphenyl)hexa-1,5-dien-3-
yl)acrylamide (102). Prepared according to the general pro-
cedure for the preparation of the amides in 87% yield (yellow so-
lid). Eluent: hexanes/ethyl acetate 1:5 v/v. Mp: 103.0–105.0 C;
IR (cm1, thin ﬁlm): 3259, 3070, 2999, 2956, 2935, 2836, 1655,
1627, 1514, 1463, 1210, 1063, 1044, 1031, 968, 869, 734; 1H
NMR (250 MHz, CDCl3): d 6.90 (s, 1H), 6.77 (d, J = 16.1 Hz, 1H),
6.46 (s, 1H), 6.29–5.97 (m, 3H), 5.91–5.70 (m, 2H), 5.61 (d,
J = 9.8 Hz, 1H), 5.18–5.03 (m, 2H), 4.87–4.72 (m, 1H), 3.86 (s, 3H),
3.85 (s, 3H), 3.78 (s, 3H), 2.50–2.39 (m, 2H); 13C NMR (62.5 MHz,
CDCl3): d 164.7 (C0), 151.4 (C0), 149.5 (C0), 143.2 (C0), 134.0 (CH),
130.9 (CH), 127.2 (CH), 126.3 (CH2), 125.0 (CH), 118.1 (CH2),
117.3 (C0), 110.0 (CH), 97.6 (CH), 56.5 (2  OCH3), 56.0 (OCH3),
50.5 (CH), 39.4 (CH2); HRMS (ESI+) m/z: Calcd for C18H24NO4
[M+H+] 318.1705, found 318.1635.
4.1.11. General procedure for the preparation of lactams
To a solution of the amides 94–102 (1.52 mmol) in CH2Cl2
(152 mL), under reﬂux and magnetic stirring, was added second
generation Grubbs catalyst (2 mol %; 0.03 mmol). After 6.0 h un-
der these conditions, the reaction was allowed to cool to room
temperature, DMSO (50 equiv relative to the catalyst) was added
and the mixture was maintained overnight under magnetic stir-
ring. After this period, the solvent was removed under reduced
pressure and the residue was subjected to ﬂash column chroma-
tography (using the eluent indicated) to afford the corresponding
lactams 103–111.4.1.11.1. (E)-6-Styryl-5,6-dihydropyridin-2(1H)-one (103).
Prepared according to the general procedure for the preparation
of lactams in 82% yield (white solid). Eluent: hexanes/ethyl acetate
1:1, 1:2 v/v. Mp: 152.8–154.2 C; IR (cm1, thin ﬁlm): 3211, 1676,
1610, 1415, 1327, 1275, 1126, 965, 816, 754; 1H NMR (250 MHz,
CDCl3): d 7.40–7.21 (m, 5H), 6.64–6.53 (m, 2H), 6.19 (dd, J = 15.8
and 7.3 Hz, 1H), 6.03 (br s, 1H), 5.95 (dd, J = 9.9 and 2.0 Hz, 1H),
4.36–4.24 (m, 1H), 2.54 (dt, J = 17.8 and 5.3 Hz, 1H), 2.36 (dddd,
J = 17.8, 9.5, 3.4 and 2.0 Hz, 1H); 13C NMR (62.5 MHz, CDCl3): d
166.2 (C0), 139.9 (CH), 135.9 (C0), 131.8 (CH), 128.5 (2  CH),
128.4 (CH), 127.9 (CH), 126.4 (2  CH), 124.4 (CH), 53.1 (CH),
30.2 (CH2); HRMS (ESI+) m/z: Calcd for C13H14NO [M+H+]
200.1075, found 200.1077.4.1.11.2. (E)-6-(2-(Triﬂuoromethyl)styryl)-5,6-dihydropyridin-
2(1H)-one (104). Prepared according to the general proce-
dure for the preparation of lactams in 64% yield (white solid).
Eluent: hexanes/ethyl acetate 1:1, 1:2 v/v. Mp: 98.1–100.0 C;
IR (cm1, thin ﬁlm): 3384, 3044, 1681, 1609, 1429, 1316, 1158,
1117, 1105, 1036, 967, 809, 766; 1H NMR (500 MHz, CDCl3): d
7.64 (d, J = 7.8 Hz, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.52 (t,
J = 7.8 Hz, 1H), 7.38 (t, J = 7.8 Hz, 1H), 6.97 (dd, J = 15.7 and
1.7 Hz, 1H), 6.63 (ddd, J = 10.0, 5.0 and 3.5 Hz, 1H), 6.18 (dd,
J = 15.7 and 7.7 Hz, 1H), 5.97 (dq, J = 10.0 and 2.0 Hz, 1H), 5.50
(br s, 1H), 4.39–4.33 (m, 1H), 2.59 (dt, J = 17.8 and 5.0 Hz, 1H),
2.41 (dddd, J = 17.8, 9.7, 3.5 and 2.0 Hz, 1H); 13C NMR
(62.5 MHz, CDCl3): d 166.0 (C0), 139.9 (CH), 135.1 (q, J = 1.6 Hz,
C0), 132.8 (CH), 131.9 (CH), 128.5 (q, J = 1.7 Hz, CH), 127.8 (CH),
127.6 (q, J = 30.0 Hz, C0), 127.6 (CH), 125.8 (q, J = 5.7 Hz, CH),
124.6 (CH), 124.2 (q, J = 274.0 Hz, C0), 53.5 (CH), 30.3 (CH2);
HRMS (ESI+) m/z: Calcd for C14H13F3NO [M+H+] 268.0949, found
268.1034.4.1.11.3. (E)-6-(4-(Triﬂuoromethyl)styryl)-5,6-dihydropyridin-
2(1H)-one (105). Prepared according to the general proce-
dure for the preparation of lactams in 60% yield (white solid). Elu-
ent: hexanes/ethyl acetate 1:1, 1:2 v/v. Mp: 129.6–131.0 C; IR
(cm1, thin ﬁlm): 3218, 3053, 1681, 1611, 1415, 1324, 1172,
1117, 1067, 1016, 973, 818, 734; 1H NMR (500 MHz, CDCl3): d
7.59 (d, J = 8.2 Hz, 2H), 7.47 (d, J = 8.2 Hz, 2H), 6.65–6.60 (m, 2H),
6.30 (dd, J = 15.9 and 7.2 Hz, 1H), 5.98 (dq, J = 10.0 and 2.0 Hz,
1H), 5.53 (br s, 1H), 4.38–4.32 (m, 1H), 2.61 (dt, J = 17.8 and
5.3 Hz, 1H), 2.41 (dddd, J = 17.8, 9.3, 3.5 and 2.0 Hz, 1H); 13C
NMR (62.5 MHz, CDCl3): d 166.3 (C0), 139.8 (CH), 139.5 (C0),
131.3 (CH), 130.5 (CH), 129.8 (q, J = 32.4 Hz, C0), 126.7 (2  CH),
125.6 (q, J = 4.0 Hz, 2  CH), 124.6 (CH), 124.1 (q, J = 272.1 Hz,
C0), 53.0 (CH), 30.1 (CH2); HRMS (ESI+) m/z: Calcd for C14H13F3NO
[M+H+] 268.0949, found 268.1065.4.1.11.4. (E)-6-(4-Methoxystyryl)-5,6-dihydropyridin-2(1H)-one
(106). Prepared according to the general procedure for the
preparation of lactams in 76% yield (white solid). Eluent: hex-
anes/ethyl acetate 1:2 v/v. Mp: 157.0–158.0 C; IR (cm1, thin
ﬁlm): 3184, 2928, 2835, 1673, 1655, 1608, 1514, 1306, 1241,
1177, 1031, 969, 850, 822, 811; 1H NMR (500 MHz, CDCl3): d
7.29 (d, J = 8.7 Hz, 2H), 6.85 (d, J = 8.7 Hz, 2H), 6.60 (ddd, J = 9.9,
5.0 and 3.0 Hz, 1H), 6.51 (d, J = 15.8 Hz, 1H), 6.04 (dd, J = 15.8 and
7.4 Hz, 1H), 5.94 (dd, J = 9.9 and 1.4 Hz, 1H), 5.80 (br s, 1H),
4.30–4.23 (m, 1H), 3.80 (s, 3H), 2.51 (dt, J = 17.8 and 5.0 Hz, 1H),
2.35 (ddt, J = 17.8, 9.9 and 3.0 Hz, 1H); 13C NMR (62.5 MHz, CDCl3):
d 166.2 (C0), 159.4 (C0), 140.0 (CH), 131.3 (CH), 128.6 (C0), 127.6
(2  CH), 126.1 (CH), 124.3 (CH), 113.9 (2  CH), 55.1 (OCH3),
53.3 (CH), 30.4 (CH2); HRMS (ESI+) m/z: Calcd for C14H17NO2
[M+H+] 230.1181, found 230.1200.
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one (107). Prepared according to the general procedure for
the preparation of lactams in 64% yield (white solid). Eluent: hex-
anes/ethyl acetate 1:1, 1:5, 1:10 v/v. Mp: 165.6–166.7 C; IR (cm1,
thin ﬁlm): 3193, 3104, 3049, 2964, 2846, 1673, 1607, 1504, 1417,
1308, 1282, 1208, 1026, 975, 825, 813; 1H NMR (500 MHz, CDCl3):
d 7.30 (d, J = 8.5 Hz, 1H), 6.79 (d, J = 15.9 Hz, 1H), 6.60 (ddd, J = 9.8,
5.1 and 3.0 Hz, 1H), 6.46 (dd, J = 8.5 and 2.3 Hz, 1H), 6.42 (d,
J = 2.3 Hz, 1H), 6.08 (dd, J = 15.9 and 7.7 Hz, 1H), 5.93 (d,
J = 9.9 Hz, 1H), 5.64 (br s, 1H), 4.30–4.22 (m, 1H), 3.81 (s, 3H),
3.80 (s, 3H), 2.49 (dt, J = 17.8 and 5.1 Hz, 1H), 2.35 (ddt, J = 17.8,
10.5 and 3.0 Hz, 1H); 13C NMR (62.5 MHz, CDCl3): d 166.1 (C0),
160.8 (C0), 157.8 (C0), 140.2 (CH), 127.7 (CH), 126.8 (CH), 126.5
(CH), 124.3 (CH), 117.7 (C0), 104.8 (CH), 98.3 (CH), 55.3 (OCH3),
55.2 (OCH3), 54.1 (CH), 30.7 (CH2); HRMS (ESI+) m/z: Calcd for
C15H18NO3 [M+H+] 260.1287, found 260.1298.
4.1.11.6. (E)-6-(3,4-Dimethoxystyryl)-5,6-dihydropyridin-2(1H)-
one (108). Prepared according to the general procedure for
the preparation of lactams in 60% yield (white solid). Eluent: hex-
anes/ethyl acetate 1:1, 1:5, 1:10 v/v. Mp: 162.7–164.3 C; IR (cm1,
thin ﬁlm): 3187, 3045, 2929, 2846, 1674, 1609, 1517, 1417, 1265,
1141, 1017, 965, 822, 807; 1H NMR (500 MHz, CDCl3): d 6.92–
6.88 (m, 2H), 6.81 (d, J = 8.8 Hz, 1H), 6.60 (ddd, J = 9.9, 4.9 and
3.0 Hz, 1H), 6.50 (d, J = 15.8 Hz, 1H), 6.05 (dd, J = 15.8 and 7.5 Hz,
1H), 5.94 (d, J = 9.9 Hz, 1H), 5.77 (br s, 1H), 4.31–4.24 (m, 1H),
3.89 (s, 3H), 3.87 (s, 3H), 2.54 (dt, J = 17.8 and 4.9 Hz, 1H), 2.37
(ddt, J = 17.8, 9.7 and 3.0 Hz, 1H); 13C NMR (62.5 MHz, CDCl3): d
166.1 (C0), 148.9 (C0), 148.8 (C0), 139.9 (CH), 131.5 (CH), 128.9
(C0), 126.3 (CH), 124.3 (CH), 119.6 (CH), 110.9 (CH), 108.7 (CH),
55.7 (OCH3), 55.6 (OCH3), 53.1 (CH), 30.3 (CH2); HRMS (ESI+) m/
z: Calcd for C15H18NO3 [M+H+] 260.1287, found 260.1298.
4.1.11.7. (E)-6-(3,5-Dimethoxystyryl)-5,6-dihydropyridin-2(1H)-
one (109). Prepared according to the general procedure for
the preparation of lactams in 70% yield (white solid). Eluent: hex-
anes/ethyl acetate 1:1, 1:5, 1:10 v/v. Mp: 101.9–103.6 C; IR (cm1,
thin ﬁlm): 3227, 2939, 2839, 1677, 1592, 1457, 1427, 1205, 1153,
1064, 969, 814; 1H NMR (250 MHz, CDCl3): d 6.60 (ddd, J = 9.9,
5.0 and 3.6 Hz, 1H), 6.61 (d, J = 2.2 Hz, 2H), 6.50 (d, J = 15.7 Hz,
1H), 6.38 (app t, J = 2.2 Hz, 1H), 6.16 (dd, J = 15.7 and 7.3 Hz, 1H),
5.95 (dd, J = 9.9 and 2.0 Hz, 1H), 5.81 (br s, 1H), 4.36–4.22 (m,
1H), 3.79 (s, 6H), 2.56 (dt, J = 17.7 and 5.0 Hz, 1H), 2.36 (dddd,
J = 17.7, 9.4, 3.6 and 2.0 Hz, 1H); 13C NMR (62.5 MHz, CDCl3,): d
166.1 (C0), 160.6 (2  C0), 139.8 (CH), 137.8 (C0), 131.5 (CH),
128.9 (CH), 124.3 (CH), 104.4 (2  CH), 100.0 (CH), 55.0 (2  OCH3),
52.8 (CH), 30.0 (CH2); HRMS (ESI+) m/z: Calcd for C15H18NO3
[M+H+] 260.1287, found 260.1298.
4.1.11.8. (E)-6-(3,4,5-Trimethoxystyryl)-5,6-dihydropyridin-
2(1H)-one (110). Prepared according to the general proce-
dure for the preparation of lactams in 97% yield (white solid). Elu-
ent: hexanes/ethyl acetate 1:1, 1:5, 1:10 v/v. Mp: 138.2–139.2 C;
IR (cm1, thin ﬁlm): 3219, 3012, 2996, 2968, 2934, 2839, 1673,
1608, 1583, 1462, 1423, 1127, 1006, 971, 815, 736; 1H NMR
(500 MHz, CDCl3): d 6.64–6, 65 (m, 3H), 6.49 (d, J = 15.7 Hz, 1H),
6.10 (dd, J = 15.7 and 7.3 Hz, 1H), 5.95 (d, J = 9.9 Hz, 1H), 6.80 (br
s, 1H), 4.29 (q, J = 7.3 Hz, 1H), 3.86 (s, 6H), 3.83 (s, 3H), 2.56 (dt,
J = 17.8 and 5.4 Hz, 1H), 2.43–2.34 (m, 1H); 13C NMR (62.5 MHz,
CDCl3): d 166.0 (C0), 153.0 (2  C0), 139.7 (CH), 137.7 (C0), 131.5
(CH), 131.4 (C0), 127.8 (CH), 124.2 (CH), 103.4 (2  CH), 60.5
(OCH3), 55.8 (2  OCH3), 52.7 (CH), 30.0 (CH2); HRMS (ESI+) m/z:
Calcd for C16H20NO4 [M+H+] 290.1392, found 290.1408.
4.1.11.9. (E)-6-(2,4,5-Trimethoxystyryl)-5,6-dihydropyridin-
2(1H)-one (111). Prepared according to the general proce-dure for the preparation of lactams in 60% yield white solid). Elu-
ent: hexanes/ethyl acetate 1:1, 1:5, 1:10 v/v. Mp: 136.8–138.6 C;
IR (cm1, thin ﬁlm): 3238, 3001, 2938, 2835, 1673, 1608, 1513,
1464, 1440, 1208, 1125, 1031, 973, 813; 1H NMR (500 MHz,
CDCl3): d 6.91 (s, 1H), 6.83 (d, J = 15.9 Hz, 1H), 6.60 (ddd, J = 9.9,
5.0 and 3.0 Hz, 1H), 6.47 (s, 1H), 6.06 (dd, J = 15.9 and 7.7 Hz,
1H), 5.93 (dd, J = 9.9 and 1.1 Hz, 1H), 5.71 (br s, 1H), 4.31–4.24
(m, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.80 (s, 3H), 2.51 (dt, J = 17.7
and 5.0 Hz, 1H), 2.36 (ddt, J = 17.7, 10.3 and 3.0 Hz, 1H); 13C NMR
(62.5 MHz, CDCl3): d 166.0 (C0), 151.3 (C0), 149.7 (C0), 143.0 (C0),
140.0 (CH), 126.4 (CH), 126.2 (CH), 124.2 (CH), 116.3 (C0), 109.8
(CH), 97.3 (CH), 56.3 (OCH3), 56.2 (OCH3), 55.8 (OCH3), 53.8 (CH),
30.5 (CH2); HRMS (ESI+) m/z: Calcd for C16H20NO4 [M+H+]
290.1392, found 290.1404.
4.2. In vitro antiproliferative assay
4.2.1. Cell lines
Human tumor cell lines U251 (glioma), MCF-7 (breast), NCI-
H460 (lung, non-small cells), OVCAR-03 (ovarian), HT-29 (colon),
786-0 (kidney), and NCI-ADR/RES (ovarian expressing phenotype
multiple drugs resistance) were obtained from National Cancer
Institute at Frederick MA-USA.
4.2.2. Cell culture
Stock cultures were grown in medium containing 5 mL RPMI
1640 (GIBCO BRL) supplemented with 5% fetal bovine serum
(FBS, GIBCO) at 37 C with 5% CO2. Penicillin: streptomicyne
(1000 lg/L:1000 U/L, 1 mL/L) were added to the experimental
cultures.
4.2.3. Antiproliferative assay
Cells in 96 well plates (100 lL cells/well) were exposed to
goniothalamin and its analogues in concentrations 0.25, 2.5, 25
and 250 lg/mL in DMSO (Merck)/RPMI at 37 C, 5% of CO2 in air
for 48 h. Doxorubicin was used as positive control (0.025, 0.25,
2.5 and 25 lg/mL). Final DMSO concentration did not affect cell
viability. Afterwards cells were ﬁxed with 50% trichloroacetic acid
(Merck) and cell proliferation determined by spectrophotometric
quantiﬁcation (540 nm) of cellular protein content using sulforho-
damine B assay.30a Using the concentration-response curve for
each cell line, the TGI (concentration that produces total growth
inhibition or cytostatic effect) were determined through non-linear
regression analysis (Table 1 and 2) using software ORIGIN 7.5
(OriginLab Corporation).30b
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